[
  {
    "id": "ind:fda.verzenio:0",
    "document_id": "doc:fda.verzenio",
    "indication": "Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",
    "initial_approval_date": "2023-03-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor)"
  },
  {
    "id": "ind:fda.verzenio:1",
    "document_id": "doc:fda.verzenio",
    "indication": "Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
    "initial_approval_date": "2018-08-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208716s001lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:fda.verzenio:2",
    "document_id": "doc:fda.verzenio",
    "indication": "Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "initial_approval_date": "2017-09-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.verzenio:3",
    "document_id": "doc:fda.verzenio",
    "indication": "Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
    "initial_approval_date": "2017-09-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib)"
  },
  {
    "id": "ind:fda.akeega:0",
    "document_id": "doc:fda.akeega",
    "indication": "AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",
    "initial_approval_date": "2018-08-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.",
    "raw_biomarkers": "deleterious or suspected deleterious BRCA-mutated (BRCAm)",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Akeega (abiraterone acetate and niraparib) in combination with prednisone"
  },
  {
    "id": "ind:fda.krazati:0",
    "document_id": "doc:fda.krazati",
    "indication": "KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2022-12-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to adagrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and that continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "KRAS G12C",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Krazati (adagrasib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2022-12-20"
  },
  {
    "id": "ind:fda.kadcyla:0",
    "document_id": "doc:fda.kadcyla",
    "indication": "KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease; or developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA.",
    "initial_approval_date": "2013-02-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Kadcyla (ado-trastuzumab emtansine)"
  },
  {
    "id": "ind:fda.kadcyla:1",
    "document_id": "doc:fda.kadcyla",
    "indication": "KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA.",
    "initial_approval_date": "2019-05-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for ado-trastuzumab emtansine.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Kadcyla (ado-trastuzumab emtansine)"
  },
  {
    "id": "ind:fda.gilotrif:0",
    "document_id": "doc:fda.gilotrif",
    "indication": "GILOTRIF is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test (1.1) Limitations of Use: Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations.",
    "initial_approval_date": "2018-01-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to afatinib for the first-line treatment of patients with metastatic non-small lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "non-resistant EGFR mutations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Gilotrif (afatinib)"
  },
  {
    "id": "ind:fda.alecensa:0",
    "document_id": "doc:fda.alecensa",
    "indication": "ALECENSA is a kinase inhibitor indicated for the adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive) as detected by an FDA-approved test.",
    "initial_approval_date": "2024-04-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)"
  },
  {
    "id": "ind:fda.alecensa:1",
    "document_id": "doc:fda.alecensa",
    "indication": "ALECENSA is a kinase inhibitor indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test.",
    "initial_approval_date": "2017-11-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to alectinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)",
    "date_regular_approval": "2017-11-06",
    "date_accelerated_approval": "2015-12-11"
  },
  {
    "id": "ind:fda.piqray:0",
    "document_id": "doc:fda.piqray",
    "indication": "PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",
    "initial_approval_date": "2024-01-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.",
    "raw_biomarkers": "HR+, HER2-negative, PIK3CA-mutated",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Piqray (alpelisib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.rybrevant:0",
    "document_id": "doc:fda.rybrevant",
    "indication": "RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.",
    "initial_approval_date": "2024-03-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "EGFR exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab-vmjw) in combination with carboplatin and pemetrexed"
  },
  {
    "id": "ind:fda.rybrevant:1",
    "document_id": "doc:fda.rybrevant",
    "indication": "RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",
    "initial_approval_date": "2024-03-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",
    "raw_biomarkers": "EGFR exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab-vmjw)",
    "date_regular_approval": "2024-03-01",
    "date_accelerated_approval": "2021-05-21"
  },
  {
    "id": "ind:fda.trisenox:0",
    "document_id": "doc:fda.trisenox",
    "indication": "TRISENOX is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
    "initial_approval_date": "2018-01-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbledt.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
    "raw_biomarkers": "t(15;17) translocation or PML/RAR-alpha gene expression",
    "raw_cancer_type": "low-risk acute promyelocytic leukemia (APL)",
    "raw_therapeutics": "Trisenox (arsenic trioxide)"
  },
  {
    "id": "ind:fda.trisenox:1",
    "document_id": "doc:fda.trisenox",
    "indication": "TRISENOX is an arsenical indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
    "initial_approval_date": "2000-09-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21248lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to arsenic trioxide for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
    "raw_biomarkers": "t(15;17) translocation or PML/RAR-alpha gene expression",
    "raw_cancer_type": "acute promyelocytic leukemia (APL)",
    "raw_therapeutics": "Trisenox (arsenic trioxide)"
  },
  {
    "id": "ind:fda.scemblix:0",
    "document_id": "doc:fda.scemblix",
    "indication": "SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
    "initial_approval_date": "2022-10-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215358s001lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:fda.scemblix:1",
    "document_id": "doc:fda.scemblix",
    "indication": "SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with Ph+ CML in CP with the T315I mutation.",
    "initial_approval_date": "2021-10-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.",
    "raw_biomarkers": "philadelphia chromosome-positive with the T315I mutation",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:fda.tecentriq:0",
    "document_id": "doc:fda.tecentriq",
    "indication": "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.",
    "initial_approval_date": "2021-10-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034Orig1s042lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab for the adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.",
    "raw_biomarkers": "PD-L1 expression on >= 1% of tumor cells",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:fda.tecentriq:1",
    "document_id": "doc:fda.tecentriq",
    "indication": "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
    "initial_approval_date": "2020-05-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s027lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
    "raw_biomarkers": "PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%])",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:fda.tecentriq:2",
    "document_id": "doc:fda.tecentriq",
    "indication": "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.",
    "initial_approval_date": "2018-12-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s009lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-squamous non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin"
  },
  {
    "id": "ind:fda.tecentriq:3",
    "document_id": "doc:fda.tecentriq",
    "indication": "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.",
    "initial_approval_date": "2019-12-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s021lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-squamous non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with paclitaxel protein-bound and carboplatin"
  },
  {
    "id": "ind:fda.tecentriq:4",
    "document_id": "doc:fda.tecentriq",
    "indication": "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.",
    "initial_approval_date": "2017-04-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761034s001lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.",
    "raw_biomarkers": "EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:fda.tecentriq:5",
    "document_id": "doc:fda.tecentriq",
    "indication": "TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
    "initial_approval_date": "2020-07-30",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
    "raw_biomarkers": "BRAF V600",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with cobimetinib and vemurafenib"
  },
  {
    "id": "ind:fda.ayvakit:0",
    "document_id": "doc:fda.ayvakit",
    "indication": "AYVAKIT is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.",
    "initial_approval_date": "2021-06-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s006lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.",
    "raw_biomarkers": "PDGFRA exon 18 mutation, including PDGFRA D842V",
    "raw_cancer_type": "unresectable or metastatic GIST",
    "raw_therapeutics": "Ayvakit (avapritinib)"
  },
  {
    "id": "ind:fda.mektovi:0",
    "document_id": "doc:fda.mektovi",
    "indication": "MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "initial_approval_date": "2018-06-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib"
  },
  {
    "id": "ind:fda.mektovi:1",
    "document_id": "doc:fda.mektovi",
    "indication": "MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.",
    "initial_approval_date": "2023-10-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib"
  },
  {
    "id": "ind:fda.blincyto:0",
    "document_id": "doc:fda.blincyto",
    "indication": "BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
    "initial_approval_date": "2024-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
    "raw_biomarkers": "CD19-positive",
    "raw_cancer_type": "b-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:fda.blincyto:1",
    "document_id": "doc:fda.blincyto",
    "indication": "BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).",
    "initial_approval_date": "2024-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).",
    "raw_biomarkers": "CD19-positive",
    "raw_cancer_type": "b-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:fda.blincyto:2",
    "document_id": "doc:fda.blincyto",
    "indication": "BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.",
    "initial_approval_date": "2024-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.",
    "raw_biomarkers": "CD19-positive philadelphia chromosome-negative",
    "raw_cancer_type": "b-cell precusor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:fda.bosulif:0",
    "document_id": "doc:fda.bosulif",
    "indication": "BOSULIF is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.",
    "initial_approval_date": "2023-09-23",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myelogenous leukemia (CML)",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:fda.bosulif:1",
    "document_id": "doc:fda.bosulif",
    "indication": "BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.",
    "initial_approval_date": "2023-09-23",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult patients with accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myelogenous leukemia (CML)",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:fda.adcetris:0",
    "document_id": "doc:fda.adcetris",
    "indication": "ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.",
    "initial_approval_date": "2023-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.",
    "raw_biomarkers": "CD30-expressing",
    "raw_cancer_type": "systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified",
    "raw_therapeutics": "Adcetris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone"
  },
  {
    "id": "ind:fda.adcetris:1",
    "document_id": "doc:fda.adcetris",
    "indication": "ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.",
    "initial_approval_date": "2023-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.",
    "raw_biomarkers": "CD30-expressing",
    "raw_cancer_type": "cutaneous analastplci large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:fda.alunbrig:0",
    "document_id": "doc:fda.alunbrig",
    "indication": "ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
    "initial_approval_date": "2020-05-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208772s008lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Alunbrig (brigatinib)"
  },
  {
    "id": "ind:fda.xeloda:0",
    "document_id": "doc:fda.xeloda",
    "indication": "XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.",
    "initial_approval_date": "2022-12-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to capecitabine for the treatment of adult patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "metastatic gastric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "Xeloda (capecitabine)"
  },
  {
    "id": "ind:fda.truqap:0",
    "document_id": "doc:fda.truqap",
    "indication": "TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",
    "initial_approval_date": "2023-11-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
    "raw_biomarkers": "HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Truqaf (capivasertib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.tabrecta:0",
    "document_id": "doc:fda.tabrecta",
    "indication": "TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.",
    "initial_approval_date": "2022-08-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.",
    "raw_biomarkers": "MET exon 14 skipping",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tabrecta (capmatinib)"
  },
  {
    "id": "ind:fda.libtayo:0",
    "document_id": "doc:fda.libtayo",
    "indication": "LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.",
    "initial_approval_date": "2022-11-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.",
    "raw_biomarkers": "no EGFR, ALK or ROS1 aberrations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Libtayo (cemiplimab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:fda.libtayo:1",
    "document_id": "doc:fda.libtayo",
    "indication": "LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.",
    "initial_approval_date": "2021-02-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to cemiplimab for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.",
    "raw_biomarkers": "high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Libtayo (cemiplimab)"
  },
  {
    "id": "ind:fda.zykadia:0",
    "document_id": "doc:fda.zykadia",
    "indication": "ZYKADIA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.",
    "initial_approval_date": "2019-03-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ceritinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:fda.erbitux:0",
    "document_id": "doc:fda.erbitux",
    "indication": "ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment.",
    "initial_approval_date": "2012-07-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab in combination with FOLFIRI for the first-line treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer as determined by an FDA-approved test.",
    "raw_biomarkers": "K-Ras wild type, EGFR-expressing",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with FOLFIRI"
  },
  {
    "id": "ind:fda.erbitux:1",
    "document_id": "doc:fda.erbitux",
    "indication": "ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy.",
    "initial_approval_date": "2012-07-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab in combination with irinotecan for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal.",
    "raw_biomarkers": "K-Ras wild-type, EGFR-expressing",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with irinotecan"
  },
  {
    "id": "ind:fda.erbitux:2",
    "document_id": "doc:fda.erbitux",
    "indication": "ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.",
    "initial_approval_date": "2012-07-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer, as determined by an FDA-approved test, who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.",
    "raw_biomarkers": "K-Ras wild type, EGFR-expressing",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab)"
  },
  {
    "id": "ind:fda.erbitux:3",
    "document_id": "doc:fda.erbitux",
    "indication": "ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.",
    "initial_approval_date": "2021-09-24",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with encorafenib"
  },
  {
    "id": "ind:fda.cotellic:0",
    "document_id": "doc:fda.cotellic",
    "indication": "COTELLIC is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.",
    "initial_approval_date": "2015-11-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Cotellic (cobimetinib) in combination with vemurafenib"
  },
  {
    "id": "ind:fda.xalkori:0",
    "document_id": "doc:fda.xalkori",
    "indication": "XALKORI is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.",
    "initial_approval_date": "2017-07-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.",
    "raw_biomarkers": "ALK or ROS1-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:fda.xalkori:1",
    "document_id": "doc:fda.xalkori",
    "indication": "XALKORI is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.",
    "initial_approval_date": "2021-01-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202570s030lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "anaplastic large cell lymphoma (ALCL)",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:fda.xalkori:2",
    "document_id": "doc:fda.xalkori",
    "indication": "XALKORI is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.",
    "initial_approval_date": "2022-07-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:fda.tafinlar:0",
    "document_id": "doc:fda.tafinlar",
    "indication": "TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.",
    "initial_approval_date": "2013-05-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib)"
  },
  {
    "id": "ind:fda.tafinlar:1",
    "document_id": "doc:fda.tafinlar",
    "indication": "TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.",
    "initial_approval_date": "2015-11-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202806s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E or BRAF V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:2",
    "document_id": "doc:fda.tafinlar",
    "indication": "TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",
    "initial_approval_date": "2018-04-30",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",
    "raw_biomarkers": "BRAF V600E or BRAF V600K",
    "raw_cancer_type": "melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:3",
    "document_id": "doc:fda.tafinlar",
    "indication": "TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",
    "initial_approval_date": "2017-06-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:4",
    "document_id": "doc:fda.tafinlar",
    "indication": "TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.",
    "initial_approval_date": "2018-05-04",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "locally advanced or metastatic anaplastic thyroid cancer (ATC)",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:5",
    "document_id": "doc:fda.tafinlar",
    "indication": "TAFINLAR is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2022-06-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "unresectable or metastatic solid tumors",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.tafinlar:6",
    "document_id": "doc:fda.tafinlar",
    "indication": "TAFINLAR is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "initial_approval_date": "2023-03-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "Tafinlar (dabrafenib) in combination with trametinib"
  },
  {
    "id": "ind:fda.vizimpro:0",
    "document_id": "doc:fda.vizimpro",
    "indication": "VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.",
    "initial_approval_date": "2018-09-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "EGFR exon 19 deletion or exon 21 L858R substitution mutations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Vizimpro (dacomitinib)"
  },
  {
    "id": "ind:fda.sprycel:0",
    "document_id": "doc:fda.sprycel",
    "indication": "SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "initial_approval_date": "2015-08-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021986s016s017lbledt.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:fda.sprycel:1",
    "document_id": "doc:fda.sprycel",
    "indication": "SPRYCEL is a kinase inhibitor indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.",
    "initial_approval_date": "2010-07-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adult patients with chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:fda.sprycel:2",
    "document_id": "doc:fda.sprycel",
    "indication": "SPRYCEL is a kinase inhibitor indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.",
    "initial_approval_date": "2006-06-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021986lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:fda.sprycel:3",
    "document_id": "doc:fda.sprycel",
    "indication": "SPRYCEL is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase.",
    "initial_approval_date": "2018-12-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "philadelphia chromosome-positive CML",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:fda.sprycel:4",
    "document_id": "doc:fda.sprycel",
    "indication": "SPRYCEL is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.",
    "initial_approval_date": "2018-12-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dasatinib in combination with chemotherapy for the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This indication is based on CA180372 (NCT01460160), a multicenter, multiple-cohort study of pediatric patients with newly diagnosed B-cell precursor Ph+ ALL, where the backbone chemotherapy regimen was AIEOP-BFM ALL 2000 multi-agent chemotherapy protocol.",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "philadelphia chromosome-positive ALL",
    "raw_therapeutics": "Sprycel (dasatinib) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.jemperli:0",
    "document_id": "doc:fda.jemperli",
    "indication": "JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).",
    "initial_approval_date": "2023-07-31",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).",
    "raw_biomarkers": "mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H)",
    "raw_cancer_type": "primary advanced or recurrent endometrial cancer",
    "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclitaxel"
  },
  {
    "id": "ind:fda.jemperli:1",
    "document_id": "doc:fda.jemperli",
    "indication": "JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.",
    "initial_approval_date": "2023-02-09",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s003s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.",
    "raw_biomarkers": "dMMR",
    "raw_cancer_type": "recurrent or advanced endometrial cancer",
    "raw_therapeutics": "Jemperli (dostarlimab)"
  },
  {
    "id": "ind:fda.jemperli:2",
    "document_id": "doc:fda.jemperli",
    "indication": "JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2022-04-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-Approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.",
    "raw_biomarkers": "dMMR",
    "raw_cancer_type": "recurrent or advanced solid tumors",
    "raw_therapeutics": "Jemperli (dostarlimab)"
  },
  {
    "id": "ind:fda.imfinzi:0",
    "document_id": "doc:fda.imfinzi",
    "indication": "IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations.",
    "initial_approval_date": "2022-11-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "raw_biomarkers": "no sensitizing EGFR mutations or ALK genomic aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Imfinzi (durvalumab) in combination with tremelimumab-actl and platinum-based chemotherapy"
  },
  {
    "id": "ind:fda.imfinzi:1",
    "document_id": "doc:fda.imfinzi",
    "indication": "IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).",
    "initial_approval_date": "2024-06-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s045lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with carboplatin and paclitaxel, followed by durvalumab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).",
    "raw_biomarkers": "mismatch repair deficient (dMMR)",
    "raw_cancer_type": "primary advanced or recurrent endometrial cancer",
    "raw_therapeutics": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel"
  },
  {
    "id": "ind:fda.orserdu:0",
    "document_id": "doc:fda.orserdu",
    "indication": "ORSERDU is an estrogen receptor antagonist indicated for treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.",
    "initial_approval_date": "2023-01-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s000correctedlbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to elacestrant for the treatment of patients who are postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.",
    "raw_biomarkers": "ER-positive, HER2-negative, ESR1-mutated",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Orserdu (elacestrant)"
  },
  {
    "id": "ind:fda.idhifa:0",
    "document_id": "doc:fda.idhifa",
    "indication": "IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "initial_approval_date": "2017-08-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "raw_biomarkers": "IDH2 mutation",
    "raw_cancer_type": "relapsed or refractory acute myeloid leukemia (AML)",
    "raw_therapeutics": "Idhifa (enasidenib)"
  },
  {
    "id": "ind:fda.braftovi:0",
    "document_id": "doc:fda.braftovi",
    "indication": "BRAFTOVI is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",
    "initial_approval_date": "2018-06-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to encorafenib in combination with binimetinib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",
    "raw_biomarkers": "BRAF V600E or BRAF V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib"
  },
  {
    "id": "ind:fda.braftovi:1",
    "document_id": "doc:fda.braftovi",
    "indication": "BRAFTOVI is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",
    "initial_approval_date": "2020-04-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with cetuximab"
  },
  {
    "id": "ind:fda.braftovi:2",
    "document_id": "doc:fda.braftovi",
    "indication": "BRAFTOVI is a kinase inhibitor indicated in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",
    "initial_approval_date": "2023-10-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to encorafenib in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib"
  },
  {
    "id": "ind:fda.rozlytrek:0",
    "document_id": "doc:fda.rozlytrek",
    "indication": "ROZLYTREK is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
    "initial_approval_date": "2019-08-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to entrectinib for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:fda.rozlytrek:1",
    "document_id": "doc:fda.rozlytrek",
    "indication": "ROZLYTREK is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "initial_approval_date": "2023-10-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009Correctedlbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "raw_biomarkers": "NTRK gene fusion",
    "raw_cancer_type": "solid tumors",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:fda.balversa:0",
    "document_id": "doc:fda.balversa",
    "indication": "BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "initial_approval_date": "2024-01-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "raw_biomarkers": "susceptible FGFR3 genetic alterations",
    "raw_cancer_type": "locally advanced or metastatic urothelial carcinoma (mUC)",
    "raw_therapeutics": "Balversa (erdafitinib)"
  },
  {
    "id": "ind:fda.tarceva:0",
    "document_id": "doc:fda.tarceva",
    "indication": "TARCEVA is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. TARCEVA is not recommended for use in combination with platinum-based chemotherapy.",
    "initial_approval_date": "2016-10-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tarceva (erlotinib)"
  },
  {
    "id": "ind:fda.afinitor:0",
    "document_id": "doc:fda.afinitor",
    "indication": "AFINITOR is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.",
    "initial_approval_date": "2012-07-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Afinitor (everolimus)"
  },
  {
    "id": "ind:fda.faslodex:0",
    "document_id": "doc:fda.faslodex",
    "indication": "FASLODEX is an estrogen receptor antagonist indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.",
    "initial_approval_date": "2017-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s034lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant)"
  },
  {
    "id": "ind:fda.faslodex:1",
    "document_id": "doc:fda.faslodex",
    "indication": "FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.",
    "initial_approval_date": "2002-04-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21344lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.",
    "raw_biomarkers": "HR+",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant)"
  },
  {
    "id": "ind:fda.faslodex:2",
    "document_id": "doc:fda.faslodex",
    "indication": "FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.",
    "initial_approval_date": "2019-03-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344s037lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant) in combination with ribociclib"
  },
  {
    "id": "ind:fda.faslodex:3",
    "document_id": "doc:fda.faslodex",
    "indication": "FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.",
    "initial_approval_date": "2017-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant) in combination with palbociclib or abemaciclib"
  },
  {
    "id": "ind:fda.lytgobi:0",
    "document_id": "doc:fda.lytgobi",
    "indication": "LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2022-09-30",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Futibatinib's package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "FGFR2 gene fusions or other rearrangements",
    "raw_cancer_type": "unresectable, locally or metastatic intrahepatic cholangiocarcinoma",
    "raw_therapeutics": "Lytgobi (futibatinib)"
  },
  {
    "id": "ind:fda.iressa:0",
    "document_id": "doc:fda.iressa",
    "indication": "IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Limitation of Use: Safety and efficacy of IRESSA have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "initial_approval_date": "2015-07-13",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 (L858R) substitution mutations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Iressa (gefitinib)"
  },
  {
    "id": "ind:fda.mylotarg:0",
    "document_id": "doc:fda.mylotarg",
    "indication": "MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older.",
    "initial_approval_date": "2020-06-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).",
    "raw_biomarkers": "CD33-positive",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin)"
  },
  {
    "id": "ind:fda.mylotarg:1",
    "document_id": "doc:fda.mylotarg",
    "indication": "MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older.",
    "initial_approval_date": "2017-09-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 2 years and older with relapsed or refractory CD33-positive acute myeloid leukemia (AML).",
    "raw_biomarkers": "CD33-positive",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin)"
  },
  {
    "id": "ind:fda.xospata:0",
    "document_id": "doc:fda.xospata",
    "indication": "XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.",
    "initial_approval_date": "2018-11-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "FLT3 mutation",
    "raw_cancer_type": "relapsed or refractory acute myeloid leukemia",
    "raw_therapeutics": "Xospata (gilteritinib)"
  },
  {
    "id": "ind:fda.gleevec:0",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "initial_approval_date": "2006-09-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s016lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:1",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.",
    "initial_approval_date": "2003-04-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021588lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:2",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
    "initial_approval_date": "2006-10-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive acute lymphoblastic leukemia",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:3",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.",
    "initial_approval_date": "2013-01-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021588s037lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive acute lymphoblastic leukemia",
    "raw_therapeutics": "Gleevec (imatinib) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.gleevec:4",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.",
    "initial_approval_date": "2006-10-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.",
    "raw_biomarkers": "platelet-derived growth factor receptor (PDGFR) gene re-arrangements",
    "raw_cancer_type": "myelodyplastic/myeloproliferative diseases (MDS/MPD)",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:5",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.",
    "initial_approval_date": "2006-10-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.",
    "raw_biomarkers": "without the D816V c-Kit mutation or with the c-Kit mutational status unknown",
    "raw_cancer_type": "aggressive systemic mastocytosis (ASM)",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:6",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.",
    "initial_approval_date": "2006-10-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.",
    "raw_biomarkers": "FIP1L1-PDGFRa fusion kinase and for patients ... who are FIP1L1-PDGFRa fusion kinase negative or unknown",
    "raw_cancer_type": "hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:7",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
    "initial_approval_date": "2003-04-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021588lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
    "raw_biomarkers": "Kit (CD117) positive",
    "raw_cancer_type": "unresectable and/or metastatic maligant gastrointestinal stromal tumors (GIST)",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.gleevec:8",
    "document_id": "doc:fda.gleevec",
    "indication": "Gleevec is a kinase inhibitor indicated for the adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.",
    "initial_approval_date": "2012-01-31",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021588s035lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to imatinib for the adjuvant treatment of adult patients following resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST).",
    "raw_biomarkers": "Kit (CD117) positive",
    "raw_cancer_type": "GIST",
    "raw_therapeutics": "Gleevec (imatinib)"
  },
  {
    "id": "ind:fda.truseltiq:0",
    "document_id": "doc:fda.truseltiq",
    "indication": "TRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "initial_approval_date": "2021-05-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to infigratinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "raw_biomarkers": "FGFR2 fusion or other rearrangement",
    "raw_cancer_type": "unresectable locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Truseltiq (infigratinib)"
  },
  {
    "id": "ind:fda.besponsa:0",
    "document_id": "doc:fda.besponsa",
    "indication": "BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.",
    "initial_approval_date": "2024-03-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to inotuzumab ozogamicin for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).",
    "raw_biomarkers": "CD22-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Besponsa (inotuzumab ozogamicin)"
  },
  {
    "id": "ind:fda.yervoy:0",
    "document_id": "doc:fda.yervoy",
    "indication": "YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.",
    "initial_approval_date": "2018-07-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s096lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.",
    "raw_biomarkers": "microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab",
    "date_regular_approval": "2025-04-08",
    "date_accelerated_approval": "2018-07-10"
  },
  {
    "id": "ind:fda.yervoy:1",
    "document_id": "doc:fda.yervoy",
    "indication": "YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab.",
    "initial_approval_date": "2020-05-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s109lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
    "raw_biomarkers": "PD-L1 >= 1% and no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab",
    "date_regular_approval": "2020-05-15",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.yervoy:2",
    "document_id": "doc:fda.yervoy",
    "indication": "YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.",
    "initial_approval_date": "2020-05-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s110lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic or recurrent non-small cell lung cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy",
    "date_regular_approval": "2020-05-26",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.tibsovo:0",
    "document_id": "doc:fda.tibsovo",
    "indication": "TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "initial_approval_date": "2022-05-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy"
  },
  {
    "id": "ind:fda.tibsovo:1",
    "document_id": "doc:fda.tibsovo",
    "indication": "TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory AML.",
    "initial_approval_date": "2018-07-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "relapsed or refractory AML",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:fda.tibsovo:2",
    "document_id": "doc:fda.tibsovo",
    "indication": "TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes.",
    "initial_approval_date": "2023-10-24",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "relapsed or refractory myelodysplastic syndromes",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:fda.tibsovo:3",
    "document_id": "doc:fda.tibsovo",
    "indication": "TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.",
    "initial_approval_date": "2021-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:fda.tykerb:0",
    "document_id": "doc:fda.tykerb",
    "indication": "TYKERB is a kinase inhibitor indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",
    "initial_approval_date": "2007-03-13",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, a trastuzumab.",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Tykerb (lapatinib) in combination with capecitabine"
  },
  {
    "id": "ind:fda.tykerb:1",
    "document_id": "doc:fda.tykerb",
    "indication": "TYKERB is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",
    "initial_approval_date": "2010-01-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s3s6lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",
    "raw_biomarkers": "HR+, HER2 overexpression",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Tykerb (lapatinib) in combination with letrozole"
  },
  {
    "id": "ind:fda.vitrakvi:0",
    "document_id": "doc:fda.vitrakvi",
    "indication": "VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test.",
    "initial_approval_date": "2018-11-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.",
    "raw_biomarkers": "NTRK gene fusion",
    "raw_cancer_type": "solid tumors",
    "raw_therapeutics": "Vitrakvi (larotrectinib)",
    "date_regular_approval": "2025-04-09",
    "date_accelerated_approval": "2018-11-26"
  },
  {
    "id": "ind:fda.revlimid:0",
    "document_id": "doc:fda.revlimid",
    "indication": "REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.",
    "initial_approval_date": "2005-12-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021880lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to lenalidomide for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.",
    "raw_biomarkers": "5q deletion",
    "raw_cancer_type": "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS)",
    "raw_therapeutics": "Revlimid (lenalidomide)"
  },
  {
    "id": "ind:fda.lorbrena:0",
    "document_id": "doc:fda.lorbrena",
    "indication": "LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.",
    "initial_approval_date": "2021-03-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to lorlatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Lorbrena (lorlatinib)"
  },
  {
    "id": "ind:fda.margenza:0",
    "document_id": "doc:fda.margenza",
    "indication": "MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.",
    "initial_approval_date": "2020-12-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Margenza (margetuximab-cmkb) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.rydapt:0",
    "document_id": "doc:fda.rydapt",
    "indication": "RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "initial_approval_date": "2017-04-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",
    "raw_biomarkers": "FLT3 mutation-positive",
    "raw_cancer_type": "acute myeloid leukemia",
    "raw_therapeutics": "Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation"
  },
  {
    "id": "ind:fda.exkivity:0",
    "document_id": "doc:fda.exkivity",
    "indication": "EXKIVITY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "initial_approval_date": "2021-09-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "raw_biomarkers": "EGFR exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Exkivity (mobocertinib)"
  },
  {
    "id": "ind:fda.nerlynx:0",
    "document_id": "doc:fda.nerlynx",
    "indication": "NERLYNX is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.",
    "initial_approval_date": "2019-10-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208051s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to neratinib for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early-stage breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib)"
  },
  {
    "id": "ind:fda.nerlynx:1",
    "document_id": "doc:fda.nerlynx",
    "indication": "NERLYNX is a kinase inhibitor indicated in combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.",
    "initial_approval_date": "2020-02-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib) in combination with capecitabine"
  },
  {
    "id": "ind:fda.tasigna:0",
    "document_id": "doc:fda.tasigna",
    "indication": "Tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "initial_approval_date": "2018-03-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s027lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid (Ph+ CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:fda.tasigna:1",
    "document_id": "doc:fda.tasigna",
    "indication": "Tasigna is a kinase inhibitor indicated for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.",
    "initial_approval_date": "2007-10-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "chronic phase or accelerated phase Ph+ CML",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:fda.tasigna:2",
    "document_id": "doc:fda.tasigna",
    "indication": "Tasigna is a kinase inhibitor indicated for the treatment of pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.",
    "initial_approval_date": "2018-03-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s027lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "Ph+ CML-CP and CML-AP",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:fda.zejula:0",
    "document_id": "doc:fda.zejula",
    "indication": "ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.",
    "initial_approval_date": "2023-04-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",
    "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated",
    "raw_cancer_type": "recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",
    "raw_therapeutics": "Zejula (niraparib)"
  },
  {
    "id": "ind:fda.opdivo:0",
    "document_id": "doc:fda.opdivo",
    "indication": "OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery.",
    "initial_approval_date": "2024-10-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s127lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.",
    "raw_biomarkers": "no known EGFR mutations or ALK rearrangement",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-doublet chemotherapy",
    "date_regular_approval": "2024-10-03",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.lynparza:0",
    "document_id": "doc:fda.lynparza",
    "indication": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "initial_approval_date": "2018-12-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "raw_biomarkers": "deleterious or suspected deleterious germline or somatic BRCA-mutated",
    "raw_cancer_type": "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:1",
    "document_id": "doc:fda.lynparza",
    "indication": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "initial_approval_date": "2020-05-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "raw_biomarkers": "HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability",
    "raw_cancer_type": "advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab"
  },
  {
    "id": "ind:fda.lynparza:2",
    "document_id": "doc:fda.lynparza",
    "indication": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "initial_approval_date": "2023-09-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "raw_biomarkers": "deleterious or suspected deleterious germline or somatic BRCA-mutated",
    "raw_cancer_type": "relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:3",
    "document_id": "doc:fda.lynparza",
    "indication": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "initial_approval_date": "2022-03-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm, HER2-negative",
    "raw_cancer_type": "high risk early breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:4",
    "document_id": "doc:fda.lynparza",
    "indication": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "initial_approval_date": "2018-01-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Olaparib's product label states that patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. The product label also states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm, HER2-negative",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:5",
    "document_id": "doc:fda.lynparza",
    "indication": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "initial_approval_date": "2019-12-27",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558Orig1s010lblrpl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm",
    "raw_cancer_type": "metastatic pancreatic adenocarcinoma",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:6",
    "document_id": "doc:fda.lynparza",
    "indication": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "initial_approval_date": "2020-05-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "raw_biomarkers": "deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:fda.lynparza:7",
    "document_id": "doc:fda.lynparza",
    "indication": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "initial_approval_date": "2023-05-31",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
    "raw_biomarkers": "deleterious or suspected deleterious BRCA-mutated",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone"
  },
  {
    "id": "ind:fda.rezlidhia:0",
    "document_id": "doc:fda.rezlidhia",
    "indication": "REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
    "initial_approval_date": "2022-12-01",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "susceptible IDH1 mutation",
    "raw_cancer_type": "relapsed or refractory acute myeloid leukemia (AML)",
    "raw_therapeutics": "Rezlidhia (olutasidenib)"
  },
  {
    "id": "ind:fda.tagrisso:0",
    "document_id": "doc:fda.tagrisso",
    "indication": "TAGRISSO is a kinase inhibitor indicated for adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "initial_approval_date": "2020-12-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R mutations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:fda.tagrisso:1",
    "document_id": "doc:fda.tagrisso",
    "indication": "TAGRISSO is a kinase inhibitor indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "initial_approval_date": "2018-04-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R mutations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:fda.tagrisso:2",
    "document_id": "doc:fda.tagrisso",
    "indication": "TAGRISSO is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "initial_approval_date": "2024-02-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy"
  },
  {
    "id": "ind:fda.tagrisso:3",
    "document_id": "doc:fda.tagrisso",
    "indication": "TAGRISSO is a kinase inhibitor indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.",
    "initial_approval_date": "2017-03-30",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.",
    "raw_biomarkers": "EGFR T790M",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:fda.ibrance:0",
    "document_id": "doc:fda.ibrance",
    "indication": "IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",
    "initial_approval_date": "2019-09-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207103s015lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:fda.ibrance:1",
    "document_id": "doc:fda.ibrance",
    "indication": "IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy.",
    "initial_approval_date": "2016-02-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207103s002lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to palbociclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.vectibix:0",
    "document_id": "doc:fda.vectibix",
    "indication": "Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) in combination with FOLFOX for first-line treatment. Limitation of Use: Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
    "initial_approval_date": "2021-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to panitumumab in combination with FOLFOX for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS, as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC). The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
    "raw_biomarkers": "wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use)",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab) in combination with folfox"
  },
  {
    "id": "ind:fda.vectibix:1",
    "document_id": "doc:fda.vectibix",
    "indication": "Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. Limitation of Use: Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
    "initial_approval_date": "2021-08-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to panitumumab for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC)following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",
    "raw_biomarkers": "wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use)",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:fda.keytruda:0",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.",
    "initial_approval_date": "2018-08-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s035lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-squamous non-small cell lung cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
  },
  {
    "id": "ind:fda.keytruda:1",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) >=1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.",
    "initial_approval_date": "2019-04-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s047lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with non-small cell lung cancer expressing PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations, and PD-L1 [Tumor Proportion Score (TPS) >= 1%",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:2",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS >=1%) as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy. The product label further states that patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.",
    "raw_biomarkers": "PD-L1 [Tumor Proportion Score (TPS) >= 1%",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:3",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) >=1] as determined by an FDA-approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) >=1] as determined by an FDA-approved test.",
    "raw_biomarkers": "PD-L1 [Combined Positive Score (CPS)] >= 1%",
    "raw_cancer_type": "metastatic or unresectable, recurrent HNSCC",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:4",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "unresectable or metastatic ... solid tumors",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:5",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "unresectable or metastatic ... colorectal cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:6",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",
    "initial_approval_date": "2023-11-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s143lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.",
    "raw_biomarkers": "HER2-positive... whose tumors express PD-L1 (CPS >= 1)",
    "raw_cancer_type": "locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy",
    "date_regular_approval": "2025-03-19",
    "date_accelerated_approval": "2023-11-16"
  },
  {
    "id": "ind:fda.keytruda:7",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.",
    "raw_biomarkers": "HER2-negative",
    "raw_cancer_type": "locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy"
  },
  {
    "id": "ind:fda.keytruda:8",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10) as determined by an FDA-approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.",
    "raw_biomarkers": "PD-L1 (CPS >= 10)",
    "raw_cancer_type": "locally advanced or metastatic esophageal or gastroesophageal junction carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:9",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",
    "raw_biomarkers": "PD-L1 (CPS >= 1)",
    "raw_cancer_type": "persistent, recurrent, or metastatic cervical cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab"
  },
  {
    "id": "ind:fda.keytruda:10",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.",
    "raw_biomarkers": "PD-L1 (CPS >= 1)",
    "raw_cancer_type": "recurrent or metastatic cervical cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:11",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDA-approved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with lenvatinib for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "raw_biomarkers": "pMMR or not MSI-H",
    "raw_cancer_type": "advanced endometrial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with lenvatinib"
  },
  {
    "id": "ind:fda.keytruda:12",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "advanced endometrial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:13",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The product label states that the safety and effectiveness of pembrolizumab in pediatric patients with TMB-H central nervous system cancers have not been established and that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, it states that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "raw_biomarkers": "TMB-H [>= 10 mutations / megabase]",
    "raw_cancer_type": "unresectable or metastatic ... solid tumors",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:fda.keytruda:14",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then pembrolizumab continued as a single agent as adjuvant treatment after surgery, of patients with high-risk early-stage triple negative breast cancer (TNBC). This indication is based on KEYNOTE-522 (NCT03036488), a randomized (2:1), multicenter, double-blind, placebo-controlled trial where the chemotherapy regimen consisted of carboplatin, paclitaxel, doxorubicin, and cyclophosphamide.",
    "raw_biomarkers": "triple-negative",
    "raw_cancer_type": "high-risk early-stage triple-negative breast cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.keytruda:15",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS >=10) as determined by an FDA approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.",
    "raw_biomarkers": "triple-negative, PD-L1 (CPS >= 10)",
    "raw_cancer_type": "locally recurrent unresectable or metastatic triple-negative breast cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.keytruda:16",
    "document_id": "doc:fda.keytruda",
    "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) >= 1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT), with or without cisplatin and then as a single agent.",
    "initial_approval_date": "2025-06-12",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s180lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin, and then as a single agent for the treatment of adult patients with resectable locally advanced head and neck squamous cell cancer (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) >= 1], as determined by an FDA-approved test.",
    "raw_biomarkers": "PD-L1 [Combined Positive Score (CPS) >= 1]",
    "raw_cancer_type": "head and neck squamous cell cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT), with or without cisplatin and then as a single agent."
  },
  {
    "id": "ind:fda.pemazyre:0",
    "document_id": "doc:fda.pemazyre",
    "indication": "PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2020-04-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "FGFR2 fusion or other rearrangement",
    "raw_cancer_type": "unresectable locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Pemazyre (pemigatinib)"
  },
  {
    "id": "ind:fda.pemazyre:1",
    "document_id": "doc:fda.pemazyre",
    "indication": "PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.",
    "initial_approval_date": "2022-08-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pemigatinib for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.",
    "raw_biomarkers": "FGFR1 rearrangement",
    "raw_cancer_type": "relapsed or refractory myeloid/lymphoid neoplasms (MLNs)",
    "raw_therapeutics": "Pemazyre (pemigatinib)"
  },
  {
    "id": "ind:fda.perjeta:0",
    "document_id": "doc:fda.perjeta",
    "indication": "PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "initial_approval_date": "2012-06-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and docetaxel"
  },
  {
    "id": "ind:fda.perjeta:1",
    "document_id": "doc:fda.perjeta",
    "indication": "PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.",
    "initial_approval_date": "2017-12-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:fda.perjeta:2",
    "document_id": "doc:fda.perjeta",
    "indication": "PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",
    "initial_approval_date": "2017-12-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:fda.phesgo:0",
    "document_id": "doc:fda.phesgo",
    "indication": "PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.",
    "initial_approval_date": "2020-06-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.phesgo:1",
    "document_id": "doc:fda.phesgo",
    "indication": "PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",
    "initial_approval_date": "2020-06-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.phesgo:2",
    "document_id": "doc:fda.phesgo",
    "indication": "PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with docetaxel for treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "initial_approval_date": "2020-06-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with docetaxel for the treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab) in combination with docetaxel"
  },
  {
    "id": "ind:fda.iclusig:0",
    "document_id": "doc:fda.iclusig",
    "indication": "ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2024-03-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The product label notes that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). This indication is based on PhALLCON (NCT03589326), a randomized, active-controlled, multicenter, open-label trial in which chemotherapy regimens were: vincristine and dexamethasone (induction, cycles 1 to 3); methotrexate and cytarabine (consolidation, cycles 4 to 9, alternating methotrexate and cytarabine); and vincristine and prednisone (maintenance, cycles 10 to 20).",
    "raw_biomarkers": "Ph+",
    "raw_cancer_type": "Ph+ ALL",
    "raw_therapeutics": "Iclusig (ponatinib) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.iclusig:1",
    "document_id": "doc:fda.iclusig",
    "indication": "ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with as monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.",
    "initial_approval_date": "2024-03-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.",
    "raw_biomarkers": "Ph+ and T315I",
    "raw_cancer_type": "Ph+ ALL",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:fda.iclusig:2",
    "document_id": "doc:fda.iclusig",
    "indication": "ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase). Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.",
    "initial_approval_date": "2016-11-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast phase. The product label states the following limitations of use: ponatinib is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.",
    "raw_biomarkers": "T315I-positive",
    "raw_cancer_type": "CML",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:fda.gavreto:0",
    "document_id": "doc:fda.gavreto",
    "indication": "GAVRETO is a kinase inhibitor indicated for treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).",
    "initial_approval_date": "2023-08-09",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to pralsetinib for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as detected by an FDA approved test (NSCLC).",
    "raw_biomarkers": "RET fusion-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Gavreto (pralsetinib)"
  },
  {
    "id": "ind:fda.gavreto:1",
    "document_id": "doc:fda.gavreto",
    "indication": "GAVRETO is a kinase inhibitor indicated for treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "initial_approval_date": "2021-11-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). This indication is based on ARROW (NCT03037385), a multicenter, open-label, multi-cohort clinical trial where all enrolled patients had papillary thyroid cancer.",
    "raw_biomarkers": "RET fusion-positive",
    "raw_cancer_type": "advanced or metastatic... thyroid cancer",
    "raw_therapeutics": "Gavreto (pralsetinib)"
  },
  {
    "id": "ind:fda.cyramza:0",
    "document_id": "doc:fda.cyramza",
    "indication": "CYRAMZA is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.",
    "initial_approval_date": "2020-05-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 (L858R)",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Cyramza (ramucirumab) in combination with erlotinib"
  },
  {
    "id": "ind:fda.augtyro:0",
    "document_id": "doc:fda.augtyro",
    "indication": "AUGTYRO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).",
    "initial_approval_date": "2023-11-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Augtyro (repotrectinib)"
  },
  {
    "id": "ind:fda.augtyro:1",
    "document_id": "doc:fda.augtyro",
    "indication": "AUGTYRO is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "initial_approval_date": "2024-06-13",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "raw_biomarkers": "NTRK gene fusions",
    "raw_cancer_type": "solid tumors",
    "raw_therapeutics": "Augtyro (repotrectinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-06-13"
  },
  {
    "id": "ind:fda.kisqali:0",
    "document_id": "doc:fda.kisqali",
    "indication": "KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",
    "initial_approval_date": "2021-12-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:fda.kisqali:1",
    "document_id": "doc:fda.kisqali",
    "indication": "KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.",
    "initial_approval_date": "2021-12-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as either an initial endocrine-based therapy or following disease progression on endocrine therapy.",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib) in combination with fulvestrant"
  },
  {
    "id": "ind:fda.rituxan:0",
    "document_id": "doc:fda.rituxan",
    "indication": "RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B- cell NHL as a single agent.",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "B-cell Non-Hodgkin's Lymphoma (NHL)",
    "raw_therapeutics": "Rituxan (rituximab)"
  },
  {
    "id": "ind:fda.rituxan:1",
    "document_id": "doc:fda.rituxan",
    "indication": "RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "B-cell Non-Hodgkin's Lymphoma (NHL)",
    "raw_therapeutics": "Rituxan (rituximab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.rituxan:2",
    "document_id": "doc:fda.rituxan",
    "indication": "RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL) non-progressing (including stable disease), low-grade, CD20 positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20 positive, B-cell Non-Hodgkin's Lymphoma (NHL) as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "Non-Hodgkin's Lymphoma (NHL)",
    "raw_therapeutics": "Rituxan (rituximab)"
  },
  {
    "id": "ind:fda.rituxan:3",
    "document_id": "doc:fda.rituxan",
    "indication": "RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL) previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin's Lymphoma (NHL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrolled of 1854 patients. The product label did not specify the name of the clinical trial name (Study 9) that administered an anthracycline-containing chemotherapy regimen, or what the specific regimen was.",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "diffuse large B-cell Non-Hodgkin's Lymhpoma (NHL)",
    "raw_therapeutics": "Rituxan (rituximab) in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens."
  },
  {
    "id": "ind:fda.rituxan:4",
    "document_id": "doc:fda.rituxan",
    "indication": "RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.",
    "initial_approval_date": "2021-12-02",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5465lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",
    "raw_therapeutics": "Rituxan (rituximab) in combination with chemotherapy"
  },
  {
    "id": "ind:fda.rituxan:5",
    "document_id": "doc:fda.rituxan",
    "indication": "RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).",
    "initial_approval_date": "2018-04-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with fludarabine and cyclophosphamide for the treatment of previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).",
    "raw_biomarkers": "CD20-positive",
    "raw_cancer_type": "Chronic Lymphocytic Leuekmia (CLL)",
    "raw_therapeutics": "Rituxan (rituximab) in combination with fludarabine and cyclophosphamide (FC)"
  },
  {
    "id": "ind:fda.rubraca:0",
    "document_id": "doc:fda.rubraca",
    "indication": "RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "initial_approval_date": "2018-04-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "raw_biomarkers": "deleterious BRCA mutation (germline and/or somatic)",
    "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "Rubraca (rucaparib)"
  },
  {
    "id": "ind:fda.rubraca:1",
    "document_id": "doc:fda.rubraca",
    "indication": "RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "initial_approval_date": "2020-05-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "raw_biomarkers": "deleterious BRCA mutation (germline and/or somatic)",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Rubraca (rucaparib)"
  },
  {
    "id": "ind:fda.trodelvy:0",
    "document_id": "doc:fda.trodelvy",
    "indication": "TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.",
    "initial_approval_date": "2021-04-07",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s005s013lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.",
    "raw_biomarkers": "triple-negative breast cancer",
    "raw_cancer_type": "unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:fda.trodelvy:1",
    "document_id": "doc:fda.trodelvy",
    "indication": "TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",
    "initial_approval_date": "2023-02-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",
    "raw_biomarkers": "HR-positive, HER2-negative (HC 0, IHC 1+, or IHC 2+/ISH-)",
    "raw_cancer_type": "locally advanced or metastatic ... breast cancer",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:fda.retevmo:0",
    "document_id": "doc:fda.retevmo",
    "indication": "RETEVMO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.",
    "initial_approval_date": "2020-05-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.",
    "raw_biomarkers": "RET fusion",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Retevmo (selpercatinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2020-05-08"
  },
  {
    "id": "ind:fda.retevmo:1",
    "document_id": "doc:fda.retevmo",
    "indication": "RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.",
    "initial_approval_date": "2024-05-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s012lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.",
    "raw_biomarkers": "RET mutation",
    "raw_cancer_type": "advanced or metastatic medullary thyroid cancer",
    "raw_therapeutics": "Retevmo (selpercatinib)",
    "date_regular_approval": "2024-09-27",
    "date_accelerated_approval": "2024-05-29"
  },
  {
    "id": "ind:fda.retevmo:2",
    "document_id": "doc:fda.retevmo",
    "indication": "RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
    "initial_approval_date": "2024-05-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s012lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
    "raw_biomarkers": "RET gene fusion",
    "raw_cancer_type": "advanced or metastatic thyroid cancer",
    "raw_therapeutics": "Retevmo (selpercatinib)",
    "date_regular_approval": "2024-06-12",
    "date_accelerated_approval": "2024-05-29"
  },
  {
    "id": "ind:fda.retevmo:3",
    "document_id": "doc:fda.retevmo",
    "indication": "RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "initial_approval_date": "2022-09-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s007lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "raw_biomarkers": "RET gene fusion",
    "raw_cancer_type": "locally advanced or metastatic solid tumors",
    "raw_therapeutics": "Retevmo (selpercatinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2022-09-21"
  },
  {
    "id": "ind:fda.lumakras:0",
    "document_id": "doc:fda.lumakras",
    "indication": "LUMAKRAS is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2021-05-28",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. The product label states that this indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "KRAS G12C",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Lumakras (sotorasib)"
  },
  {
    "id": "ind:fda.talzenna:0",
    "document_id": "doc:fda.talzenna",
    "indication": "TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.",
    "initial_approval_date": "2018-10-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.",
    "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Talzenna (talazoparib)"
  },
  {
    "id": "ind:fda.talzenna:1",
    "document_id": "doc:fda.talzenna",
    "indication": "TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "initial_approval_date": "2023-06-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
    "raw_biomarkers": "HRR gene-mutated",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Talzenna (talazoparib) in combination with enzalutamide"
  },
  {
    "id": "ind:fda.tazverik:0",
    "document_id": "doc:fda.tazverik",
    "indication": "TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2023-11-16",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "EZH2 mutation positive",
    "raw_cancer_type": "follicular lymphoma",
    "raw_therapeutics": "Tazverik (tazemetostat)"
  },
  {
    "id": "ind:fda.tepmetko:0",
    "document_id": "doc:fda.tepmetko",
    "indication": "TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.",
    "initial_approval_date": "2021-02-03",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.",
    "raw_biomarkers": "MET exon 14 skipping alterations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Tepmetko (tepotinib)",
    "date_regular_approval": "2024-02-15",
    "date_accelerated_approval": "2021-02-03"
  },
  {
    "id": "ind:fda.mekinist:0",
    "document_id": "doc:fda.mekinist",
    "indication": "MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Mekinist (trametinib)"
  },
  {
    "id": "ind:fda.mekinist:1",
    "document_id": "doc:fda.mekinist",
    "indication": "MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:2",
    "document_id": "doc:fda.mekinist",
    "indication": "MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "melanoma",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:3",
    "document_id": "doc:fda.mekinist",
    "indication": "MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:4",
    "document_id": "doc:fda.mekinist",
    "indication": "MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "locally advanced or metastatic anaplastic thyroid cancer",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:5",
    "document_id": "doc:fda.mekinist",
    "indication": "MEKINIST is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Limitations of Use: MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted accelerated approval to trametinib in combination with dabrafenib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. The product label specifies that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Furthermore, the product label states a Limitation of Use: trametinib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "unresectable or metastatic solid tumors",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:fda.mekinist:6",
    "document_id": "doc:fda.mekinist",
    "indication": "MEKINIST is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "Mekinist (trametinib) i combination with dabrafenib"
  },
  {
    "id": "ind:fda.herceptin:0",
    "document_id": "doc:fda.herceptin",
    "indication": "Herceptin is a HER2/neu receptor antagonist indicated for the treatment of HER2 -overexpressing breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin.",
    "initial_approval_date": "2008-01-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103792s5175lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer. The product label specifies to select  patients for therapy based on an FDA-approved companion diagnostic for herceptin.",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:fda.herceptin:1",
    "document_id": "doc:fda.herceptin",
    "indication": "Herceptin is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin.",
    "initial_approval_date": "2010-10-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab.",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "metastatic gastric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:fda.enhertu:0",
    "document_id": "doc:fda.enhertu",
    "indication": "ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.",
    "initial_approval_date": "2022-05-04",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s017s020lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.",
    "raw_biomarkers": "HER2-positive (IHC 3+ or ISH positive)",
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)",
    "date_regular_approval": "2022-05-04",
    "date_accelerated_approval": "2019-12-20"
  },
  {
    "id": "ind:fda.enhertu:1",
    "document_id": "doc:fda.enhertu",
    "indication": "ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.",
    "initial_approval_date": "2022-08-05",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s022lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.",
    "raw_biomarkers": "HER2-low (IHC 1+ or IHC2+/ISH-)",
    "raw_cancer_type": "unresectable or metastatic ... breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:fda.enhertu:2",
    "document_id": "doc:fda.enhertu",
    "indication": "ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",
    "initial_approval_date": "2022-08-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. The product label states that these indications are approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",
    "raw_biomarkers": "HER2 (ERBB2) mutations",
    "raw_cancer_type": "unresectable or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2022-08-11"
  },
  {
    "id": "ind:fda.enhertu:3",
    "document_id": "doc:fda.enhertu",
    "indication": "ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.",
    "initial_approval_date": "2021-01-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.",
    "raw_biomarkers": "HER2-positive (IHC 3+ or IHC 2+/ISH positive)",
    "raw_cancer_type": "locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:fda.enhertu:4",
    "document_id": "doc:fda.enhertu",
    "indication": "ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",
    "initial_approval_date": "2024-04-05",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",
    "raw_biomarkers": "HER2-positive (IHC 3+)",
    "raw_cancer_type": "unresectable or metastatic solid tumors",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2022-08-11"
  },
  {
    "id": "ind:fda.imjudo:0",
    "document_id": "doc:fda.imjudo",
    "indication": "IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.",
    "initial_approval_date": "2022-11-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "raw_biomarkers": "no sensitizing EGFR mutation or ALK genomic tumor aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Imjudo (tremelimumab-actl) in combination with durvalumab and platinum-based chemotherapy"
  },
  {
    "id": "ind:fda.tukysa:0",
    "document_id": "doc:fda.tukysa",
    "indication": "TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",
    "initial_approval_date": "2020-04-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "advanced unresectable or metastatic breast cancer",
    "raw_therapeutics": "Tukysa (tucatinib) in combination with trastuzumab or capecitabine"
  },
  {
    "id": "ind:fda.tukysa:1",
    "document_id": "doc:fda.tukysa",
    "indication": "TUKYSA is a kinase inhibitor indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
    "initial_approval_date": "2023-01-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The label notes that this indication is approved under accelerated approval based on tumor response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This indication is based on MOUNTAINEER (NCT03043313), an open-label, multicenter trial where RAS status was performed as standard of care prior to study entry based on expanded RAS testing including KRAS exons 2, 3, and 4 and NRAS exons 2, 3, and 4.",
    "raw_biomarkers": "RAS wild-type, HER2-positive",
    "raw_cancer_type": "unresectable or metastatic colorectal cancer",
    "raw_therapeutics": "Tukysa (tucatinib) in combination with trastuzumab"
  },
  {
    "id": "ind:fda.zelboraf:0",
    "document_id": "doc:fda.zelboraf",
    "indication": "ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.",
    "initial_approval_date": "2011-08-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Zelboraf (vemurafenib)"
  },
  {
    "id": "ind:fda.zelboraf:1",
    "document_id": "doc:fda.zelboraf",
    "indication": "ZELBORAF is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.",
    "initial_approval_date": "2017-11-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.",
    "raw_biomarkers": "BRAF V600",
    "raw_cancer_type": "Erdheim-Chester Disease",
    "raw_therapeutics": "Zelboraf (vemurafenib)"
  },
  {
    "id": "ind:fda.tagrisso:4",
    "document_id": "doc:fda.tagrisso",
    "indication": "TAGRISSO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "initial_approval_date": "2024-09-25",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s143lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "osimertinib"
  },
  {
    "id": "ind:fda.rybrevant:2",
    "document_id": "doc:fda.rybrevant",
    "indication": "RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "initial_approval_date": "2024-08-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab-vmjw) in combination with lazertinib"
  },
  {
    "id": "ind:fda.lazcluze:0",
    "document_id": "doc:fda.lazcluze",
    "indication": "LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "initial_approval_date": "2024-08-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "lazertinib in combination with amivantamab"
  },
  {
    "id": "ind:fda.rybrevant:3",
    "document_id": "doc:fda.rybrevant",
    "indication": "RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",
    "initial_approval_date": "2024-09-19",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf",
    "description": "The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "amivantamab in combination with carboplatin and pemetrexed"
  },
  {
    "id": "ind:fda.elahere:0",
    "document_id": "doc:fda.elahere",
    "indication": "ELAHERE is a folate receptor alpha (FR\u03b1)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.",
    "initial_approval_date": "2024-03-22",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.",
    "raw_biomarkers": "folate receptor-alpha tumor expression",
    "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal",
    "raw_therapeutics": "mirvetuximab soravtansine-gynx"
  },
  {
    "id": "ind:fda.ojemda:0",
    "document_id": "doc:fda.ojemda",
    "indication": "OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",
    "initial_approval_date": "2024-04-23",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "BRAF fusion or rearrangement, or BRAF V600 mutation",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "tovorafenib",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-04-23"
  },
  {
    "id": "ind:fda.imfinzi:2",
    "document_id": "doc:fda.imfinzi",
    "indication": "IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.",
    "initial_approval_date": "2024-08-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",
    "raw_biomarkers": "no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "durvalumab in combination with platinum-containing chemotherapy"
  },
  {
    "id": "ind:fda.krazati:1",
    "document_id": "doc:fda.krazati",
    "indication": "KRAZATI is an inhibitor of the RAS GTPase family indicated in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.",
    "initial_approval_date": "2024-06-21",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216340s005lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) and that continued approval for this indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.",
    "raw_biomarkers": "KRAS G12C",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "Krazati (adagrasib) in combination with cetuximab",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-06-21"
  },
  {
    "id": "ind:fda.voranigo:0",
    "document_id": "doc:fda.voranigo",
    "indication": "VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "initial_approval_date": "2024-08-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
    "raw_biomarkers": "IDH1 or IDH2 mutations",
    "raw_cancer_type": "astrocytoma or oligodendroglioma",
    "raw_therapeutics": "vorasidenib"
  },
  {
    "id": "ind:fda.kisqali:2",
    "document_id": "doc:fda.kisqali",
    "indication": "KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.",
    "initial_approval_date": "2024-09-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.",
    "raw_biomarkers": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "ribociclib in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:fda.opdivo:1",
    "document_id": "doc:fda.opdivo",
    "indication": "OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab.",
    "initial_approval_date": "2020-05-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s080lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",
    "raw_biomarkers": "PD-L1 (>= 1%)",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "nivolumab in combination with ipilimumab",
    "date_regular_approval": "2020-05-15",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.opdivo:2",
    "document_id": "doc:fda.opdivo",
    "indication": "OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy.",
    "initial_approval_date": "2020-05-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s082lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "raw_biomarkers": "no EGFR or ALK genomic tumor aberrations",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy",
    "date_regular_approval": "2025-05-26",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.opdivo:3",
    "document_id": "doc:fda.opdivo",
    "indication": "OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",
    "initial_approval_date": "2018-07-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",
    "raw_biomarkers": "microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "nivolumab as a single agent",
    "date_regular_approval": "2024-04-08",
    "date_accelerated_approval": "2018-07-10"
  },
  {
    "id": "ind:fda.itovebi:0",
    "document_id": "doc:fda.itovebi",
    "indication": "ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",
    "initial_approval_date": "2024-10-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",
    "raw_biomarkers": "PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "inavolisib in combination with palbociclib and fulvestrant"
  },
  {
    "id": "ind:fda.vyloy:0",
    "document_id": "doc:fda.vyloy",
    "indication": "VYLOY is a claudin 18.2-directed cytolytic antibody and is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.",
    "initial_approval_date": "2024-10-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",
    "raw_biomarkers": "human epidermal growth factor receptor 2 (HER2)-negative .. claudin (CLDN) 18.2 positive",
    "raw_cancer_type": "gastric or gastroesophageal junction adenocarcinoma",
    "raw_therapeutics": "zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy"
  },
  {
    "id": "ind:fda.ziihera:0",
    "document_id": "doc:fda.ziihera",
    "indication": "ZIHERA is a bispecific HER2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2024-11-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "HER2-positive (IHC 3+)",
    "raw_cancer_type": "biliary tract cancer (BTC)",
    "raw_therapeutics": "zanidatamab",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-11-20"
  },
  {
    "id": "ind:fda.bizengri:0",
    "document_id": "doc:fda.bizengri",
    "indication": "BIZENGRI is a bispecific HER2- and HER3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2024-12-04",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "NGR1 gene fusion",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "zenocutuzumab-zbco",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-12-04"
  },
  {
    "id": "ind:fda.bizengri:1",
    "document_id": "doc:fda.bizengri",
    "indication": "BIZENGRI is a bispecific HER2- and HER3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2024-12-04",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "NRG1 gene fusion",
    "raw_cancer_type": "pancreatic adenocarcinoma",
    "raw_therapeutics": "zenocutuzumab-zbco",
    "date_regular_approval": null,
    "date_accelerated_approval": "2024-12-04"
  },
  {
    "id": "ind:fda.ensacove:0",
    "document_id": "doc:fda.ensacove",
    "indication": "ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.",
    "initial_approval_date": "2024-12-18",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "ensartinib"
  },
  {
    "id": "ind:fda.braftovi:3",
    "document_id": "doc:fda.braftovi",
    "indication": "BRAFTOVI is a kinase inhibitor indicated in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",
    "initial_approval_date": "2024-12-20",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Furthermore, it states that encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with cetuximab and mFOLFOX6"
  },
  {
    "id": "ind:fda.scemblix:2",
    "document_id": "doc:fda.scemblix",
    "indication": "SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2024-10-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:fda.revuforj:0",
    "document_id": "doc:fda.revuforj",
    "indication": "REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.",
    "initial_approval_date": "2024-11-15",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
    "raw_biomarkers": "KMT2A translocation",
    "raw_cancer_type": "acute leukemia",
    "raw_therapeutics": "Revuforj (revumenib)"
  },
  {
    "id": "ind:fda.afinitor:1",
    "document_id": "doc:fda.afinitor",
    "indication": "AFINITOR is a kinase inhibitor indicated for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.",
    "initial_approval_date": "2012-04-26",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s017lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.",
    "raw_biomarkers": "TSC1/2",
    "raw_cancer_type": "renal angiomyolipoma",
    "raw_therapeutics": "everolimus",
    "date_regular_approval": "2016-02-16",
    "date_accelerated_approval": "2012-04-26"
  },
  {
    "id": "ind:fda.afinitor:2",
    "document_id": "doc:fda.afinitor",
    "indication": "AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.",
    "initial_approval_date": "2010-10-29",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022334s032,203985s010lbl.pdf",
    "description": "The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.",
    "raw_biomarkers": "TSC1/2",
    "raw_cancer_type": "subependymal giant cell astrocytoma",
    "raw_therapeutics": "everolimus",
    "date_regular_approval": "2016-01-29",
    "date_accelerated_approval": "2010-10-29"
  },
  {
    "id": "ind:fda.opdivo:4",
    "document_id": "doc:fda.opdivo",
    "indication": "OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.",
    "initial_approval_date": "2018-07-10",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.",
    "raw_biomarkers": "microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "nivolumab in combination with ipilimumab",
    "date_regular_approval": "2025-04-08",
    "date_accelerated_approval": "2018-07-10"
  },
  {
    "id": "ind:fda.ibtrozi:0",
    "document_id": "doc:fda.ibtrozi",
    "indication": "IBTROZI is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).",
    "initial_approval_date": "2015-06-11",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The package insert instructs to select patients based on the presence of ROS1 rearrangements in tumor specimen(s).",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "taletrectinib",
    "date_regular_approval": "2025-06-11",
    "date_accelerated_approval": null
  },
  {
    "id": "ind:fda.emrelis:0",
    "document_id": "doc:fda.emrelis",
    "indication": "EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.",
    "initial_approval_date": "2025-05-14",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin, a c-Met-directed antibody and microtubule inhibitor conjugate, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining]",
    "raw_cancer_type": "non-squamous non-small cell lung cancer",
    "raw_therapeutics": "telisotuzumab vedotin",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-05-14"
  },
  {
    "id": "ind:fda.avmapki-fakzynja:0",
    "document_id": "doc:fda.avmapki-fakzynja",
    "indication": "AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.",
    "initial_approval_date": "2025-05-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.",
    "raw_biomarkers": "KRAS-mutated",
    "raw_cancer_type": "low-grade serous ovarian cancer (LGSOC)",
    "raw_therapeutics": "avutometinib; defactinib",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-05-08"
  },
  {
    "id": "ind:fda.datroway:0",
    "document_id": "doc:fda.datroway",
    "indication": "DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.",
    "initial_approval_date": "2025-06-23",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with locally advanced or metastatic epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. This approval is based on two clinical studies: TROPION-Lung05 and TROPION-Lung01, where efficacy was assessed in 114 patients with EGFR-mutated NSCLC. Fifty-three percent (53%) of patients had exon 19 deletions, 34% had exon 21 L858R mutations, 28% had T790M mutations, 2.6% had exon 20 insertion mutations, and 14% had other EGFR mutations.",
    "raw_biomarkers": "EGFR-mutated",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Datroway (datopotamab deruxtecan-dlnk)",
    "date_regular_approval": "2025-06-23",
    "date_accelerated_approval": "2025-06-23",
    "status": "Accelerated"
  },
  {
    "id": "ind:fda.datroway:1",
    "document_id": "doc:fda.datroway",
    "indication": "DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.",
    "initial_approval_date": "2025-01-17",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.",
    "raw_biomarkers": "(HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-)",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Datroway (datopotamab deruxtecan-dlnk)",
    "date_regular_approval": "2025-01-17",
    "date_accelerated_approval": null,
    "status": "Approved"
  },
  {
    "id": "ind:fda.zegfrovy:0",
    "document_id": "doc:fda.zegfrovy",
    "indication": "ZEGFROVY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "initial_approval_date": "2025-07-02",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to sunvozertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",
    "raw_biomarkers": "EGFR exon 20 insertion mutations",
    "raw_cancer_type": "non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Zegfrovy (sunvozertinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-07-02",
    "status": "Accelerated"
  },
  {
    "id": "ind:fda.hernexeos:0",
    "document_id": "doc:fda.hernexeos",
    "indication": "HERNEXEOS is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "initial_approval_date": "2025-08-08",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219042s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to zongertinib for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "raw_biomarkers": "HER2 (ERBB2) tyrosine kinase domain activating mutations",
    "raw_cancer_type": "non-squamous non-small cell lung cancer",
    "raw_therapeutics": "Hernexeos (zongertinib)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-08-08",
    "status": "Accelerated"
  },
  {
    "id": "ind:ema.adcetris:0",
    "document_id": "doc:ema.adcetris",
    "indication": "ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine"
  },
  {
    "id": "ind:ema.adcetris:1",
    "document_id": "doc:ema.adcetris",
    "indication": "ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:ema.adcetris:2",
    "document_id": "doc:ema.adcetris",
    "indication": "ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): (i) following ASCT, or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hodgkin Lymphoma (HL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:ema.adcetris:3",
    "document_id": "doc:ema.adcetris",
    "indication": "ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cutaneous T-cell lymphoma (CTCL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:ema.afinitor:0",
    "document_id": "doc:ema.afinitor",
    "indication": "Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Afinitor (everolimus) in combination with exemestane"
  },
  {
    "id": "ind:ema.akeega:0",
    "document_id": "doc:ema.akeega",
    "indication": "Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Metastatic castration-resistant prostate cancer",
    "raw_therapeutics": "Akeega (abiraterone acetate and niraparib)"
  },
  {
    "id": "ind:ema.alecensa:0",
    "document_id": "doc:ema.alecensa",
    "indication": "Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)"
  },
  {
    "id": "ind:ema.alecensa:1",
    "document_id": "doc:ema.alecensa",
    "indication": "Alecensa as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)"
  },
  {
    "id": "ind:ema.alecensa:2",
    "document_id": "doc:ema.alecensa",
    "indication": "Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the adjuvant treatment following complete tumor resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alecensa (alectinib)"
  },
  {
    "id": "ind:ema.alunbrig:0",
    "document_id": "doc:ema.alunbrig",
    "indication": "Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alunbrig (brigatinib)"
  },
  {
    "id": "ind:ema.alunbrig:1",
    "document_id": "doc:ema.alunbrig",
    "indication": "Alunbrig is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Alunbrig (brigatinib)"
  },
  {
    "id": "ind:ema.avastin:0",
    "document_id": "doc:ema.avastin",
    "indication": "Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Avastin (bevacizumab) in combination with erlotinib"
  },
  {
    "id": "ind:ema.ayvakyt:0",
    "document_id": "doc:ema.ayvakyt",
    "indication": "AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized avapritinib as a monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) p.D842V variant.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastrointestinal stromal tumours (GIST)",
    "raw_therapeutics": "Ayvakyt (avapritinib)"
  },
  {
    "id": "ind:ema.besponsa:0",
    "document_id": "doc:ema.besponsa",
    "indication": "BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Besponsa (inotuzumab ozogamicin)"
  },
  {
    "id": "ind:ema.blincyto:0",
    "document_id": "doc:ema.blincyto",
    "indication": "BLINCYTO is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.blincyto:1",
    "document_id": "doc:ema.blincyto",
    "indication": "BLINCYTO is indicated as monotherapy for the treatment of adults with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precusor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
    "raw_biomarkers": "Philadelphia chromosome negative CD19 positive",
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.blincyto:2",
    "document_id": "doc:ema.blincyto",
    "indication": "BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.",
    "initial_approval_date": "2025-02-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.",
    "raw_biomarkers": "Philadelphia chromosome negative CD19 positive",
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.blincyto:3",
    "document_id": "doc:ema.blincyto",
    "indication": "BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with high-risk first relapsed Philadelphia chromosome-negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.",
    "initial_approval_date": "2025-02-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.",
    "raw_biomarkers": "Philadelphia chromosome negative CD19 positive",
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.blincyto:4",
    "document_id": "doc:ema.blincyto",
    "indication": "BLINCYTO is indicated as monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome negative CD19 positive B-cell precusor acute lymphoblastic leukaemia (ALL).",
    "initial_approval_date": "2025-02-10",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.",
    "raw_biomarkers": "Philadelphia chromosome negative CD19 positive",
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:ema.bosulif:0",
    "document_id": "doc:ema.bosulif",
    "indication": "Bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).",
    "initial_approval_date": "2025-08-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:ema.bosulif:1",
    "document_id": "doc:ema.bosulif",
    "indication": "Bosulif is indicated for the treatment of adult patients with accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.",
    "initial_approval_date": "2025-08-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with accelerated phase, and blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:ema.bosulif:2",
    "document_id": "doc:ema.bosulif",
    "indication": "Bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.",
    "initial_approval_date": "2025-08-26",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:ema.braftovi:0",
    "document_id": "doc:ema.braftovi",
    "indication": "Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Encorafenib and Binimetinib"
  },
  {
    "id": "ind:ema.braftovi:1",
    "document_id": "doc:ema.braftovi",
    "indication": "Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF p.V600E variant, who have received prior systemic therapy. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Encorafenib and Cetuximab"
  },
  {
    "id": "ind:ema.braftovi:2",
    "document_id": "doc:ema.braftovi",
    "indication": "Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib"
  },
  {
    "id": "ind:ema.caprelsa:0",
    "document_id": "doc:ema.caprelsa",
    "indication": "Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Medullary thyroid cancer",
    "raw_therapeutics": "Caprelsa (vandetanib)"
  },
  {
    "id": "ind:ema.cotellic:0",
    "document_id": "doc:ema.cotellic",
    "indication": "Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Cobimetinib and vemurafenib"
  },
  {
    "id": "ind:ema.cyramza:0",
    "document_id": "doc:ema.cyramza",
    "indication": "Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Cyramza (ramucirumab) and erlotinib"
  },
  {
    "id": "ind:ema.taxotere:0",
    "document_id": "doc:ema.taxotere",
    "indication": "TAXOTERE in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Taxotere (docetaxel)"
  },
  {
    "id": "ind:ema.enhertu:0",
    "document_id": "doc:ema.enhertu",
    "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.enhertu:1",
    "document_id": "doc:ema.enhertu",
    "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. For the purposes of this indication, HER2-low is defined as a score of IHC 1+ or IHC 2+/ISH-, as assessed by a CE-marked IVD medical device or alternative valid test.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.enhertu:2",
    "document_id": "doc:ema.enhertu",
    "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.enhertu:3",
    "document_id": "doc:ema.enhertu",
    "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.enhertu:4",
    "document_id": "doc:ema.enhertu",
    "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.",
    "initial_approval_date": "2025-04-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.",
    "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:ema.erbitux:0",
    "document_id": "doc:ema.erbitux",
    "indication": "Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized cetuximab as a single agent for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab)"
  },
  {
    "id": "ind:ema.erbitux:1",
    "document_id": "doc:ema.erbitux",
    "indication": "Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with irinotecan-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with irinotecan"
  },
  {
    "id": "ind:ema.erbitux:2",
    "document_id": "doc:ema.erbitux",
    "indication": "Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with 5-fluorouracil and oxaliplatin"
  },
  {
    "id": "ind:ema.faslodex:0",
    "document_id": "doc:ema.faslodex",
    "indication": "Faslodex is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized fulvestrant as a monotherapy for the treatment of patients who are postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer. These patients should not have been previously treated with endocrine therapy, or have had disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant)"
  },
  {
    "id": "ind:ema.faslodex:1",
    "document_id": "doc:ema.faslodex",
    "indication": "Faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant) in combination with palbociclib"
  },
  {
    "id": "ind:ema.gavreto:0",
    "document_id": "doc:ema.gavreto",
    "indication": "Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pralsetinib as a monotherapy treatment for adult patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Gavreto (pralsetinib)",
    "status": "Withdrawn"
  },
  {
    "id": "ind:ema.iressa:0",
    "document_id": "doc:ema.iressa",
    "indication": "IRESSA is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized gefitinib as a monotherapy treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating variants of EGFR-TK.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Iressa (gefitinib)"
  },
  {
    "id": "ind:ema.giotrif:0",
    "document_id": "doc:ema.giotrif",
    "indication": "GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized afatinib as a monotherapy indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR variants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Giotrif (afatinib)"
  },
  {
    "id": "ind:ema.herceptin:0",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic breast cancer (MBC)",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:ema.herceptin:1",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic breast cancer (MBC)",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:ema.herceptin:2",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic breast cancer (MBC)",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:ema.herceptin:3",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "metastatic breast cancer (MBC)",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:ema.herceptin:4",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:ema.herceptin:5",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with paclitaxel or docetaxel"
  },
  {
    "id": "ind:ema.herceptin:6",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with adjuvant chemotherapy containing docetaxel and carboplatin"
  },
  {
    "id": "ind:ema.herceptin:7",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with neoadjuvant chemotherapy"
  },
  {
    "id": "ind:ema.herceptin:8",
    "document_id": "doc:ema.herceptin",
    "indication": "Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
    "raw_biomarkers": null,
    "raw_cancer_type": "adenocracinoma of the stomach or gastroesophageal junction",
    "raw_therapeutics": "Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin"
  },
  {
    "id": "ind:ema.ibrance:0",
    "document_id": "doc:ema.ibrance",
    "indication": "IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:ema.ibrance:1",
    "document_id": "doc:ema.ibrance",
    "indication": "IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib) in combination with fulvestrant"
  },
  {
    "id": "ind:ema.glivec:0",
    "document_id": "doc:ema.glivec",
    "indication": "Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:1",
    "document_id": "doc:ema.glivec",
    "indication": "Glivec is indicated for the treatment of adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:2",
    "document_id": "doc:ema.glivec",
    "indication": "Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:3",
    "document_id": "doc:ema.glivec",
    "indication": "Glivec is indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:4",
    "document_id": "doc:ema.glivec",
    "indication": "Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Myelodysplastic/myeloproliferative diseases (MDS/MPD)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:5",
    "document_id": "doc:ema.glivec",
    "indication": "Glivec is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with a FIP1L1::PDGFRA rearrangement.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:6",
    "document_id": "doc:ema.glivec",
    "indication": "Glivec is indicated for the treatment of the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastrointestinal Stromal Tumor (GIST)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.glivec:7",
    "document_id": "doc:ema.glivec",
    "indication": "Glivec is indicated for the treatment of the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized imatinib for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD 117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not received adjuvant treatment.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastrointestinal Stromal Tumor (GIST)",
    "raw_therapeutics": "Imatinib"
  },
  {
    "id": "ind:ema.iclusig:0",
    "document_id": "doc:ema.iclusig",
    "indication": "Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the p.T315I variant.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:ema.iclusig:1",
    "document_id": "doc:ema.iclusig",
    "indication": "Iclusig is indicated in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) ",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:ema.imfinzi:0",
    "document_id": "doc:ema.imfinzi",
    "indication": "IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on >= 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized durvalumab as a monotherapy for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 on >= 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Imfinzi (durvalumab)"
  },
  {
    "id": "ind:ema.imfinzi:1",
    "document_id": "doc:ema.imfinzi",
    "indication": "IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Imfinzi (durvalumab) in combination with tremelimumab and platinum-based chemotherapy."
  },
  {
    "id": "ind:ema.imfinzi:2",
    "document_id": "doc:ema.imfinzi",
    "indication": "IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",
    "initial_approval_date": "2024-08-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-1049-ws-2463-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",
    "raw_biomarkers": "mismatch repair deficient (dMMR) or mismatch repair proficient (pMMR).",
    "raw_cancer_type": "Endometrial cancer",
    "raw_therapeutics": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) as monotherapy for endometrial cancer that is mismatch repair deficient (dMMR) or Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) in combination with olaparib for endometrial cancer that is mismatch repair proficient (pMMR)."
  },
  {
    "id": "ind:ema.imfinzi:3",
    "document_id": "doc:ema.imfinzi",
    "indication": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements.",
    "initial_approval_date": "2025-06-18",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-004771-ii-0064-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no EGFR mutations or ALK rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",
    "raw_biomarkers": "no EGFR mutations or ALK rearrangements",
    "raw_cancer_type": "NSCLC",
    "raw_therapeutics": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment"
  },
  {
    "id": "ind:ema.imjudo:0",
    "document_id": "doc:ema.imjudo",
    "indication": "IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Imjudo (tremelimumab) in combination with durvalumab and platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.jemperli:0",
    "document_id": "doc:ema.jemperli",
    "indication": "JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Endometrial cancer (EC)",
    "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel",
    "status": "Superseded"
  },
  {
    "id": "ind:ema.jemperli:1",
    "document_id": "doc:ema.jemperli",
    "indication": "JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Endometrial cancer (EC)",
    "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel"
  },
  {
    "id": "ind:ema.keytruda:0",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:1",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
  },
  {
    "id": "ind:ema.keytruda:2",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a >= 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung carcinoma whose tumors express PD-L1 with a >= 1% tumor proportion score (TPS) and who have recieved at least one prior chemotherapy regime. Patients with EGFR or ALK positive tumor mutations should also have received targeted therapy before receiving pembrolizumab.",
    "raw_biomarkers": null,
    "raw_cancer_type": "non-small cell lung carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:3",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 with a combined positive score (CPS) >= 10.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:4",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "raw_biomarkers": null,
    "raw_cancer_type": "head and neck squamous cell carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:5",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a >= 50% TPS and progressing on or after platinum -containing chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors express PD-L1 with a tumor proportion score >= 50% and who have progressed on or after platinum-containing chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "head and neck squamous cell carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:6",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA as monotherapy is indicated for adults with MSI-H or dMMR colorectal cancer in the following settings: first-line treatment of metastatic colorectal cancer; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine -based combination therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:7",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Endometrial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:8",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "gastric, small intestine, or biliary cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:9",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA, in combination with platinum and fluoropyrimidine -based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS >= 10.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy"
  },
  {
    "id": "ind:ema.keytruda:10",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as a monotherapy for the adjuvant treatment after surgery, of adult patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:ema.keytruda:11",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS >= 10 and who have not received prior chemotherapy for metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.keytruda:12",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cervical cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy with or without bevacizumab"
  },
  {
    "id": "ind:ema.keytruda:13",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy"
  },
  {
    "id": "ind:ema.keytruda:14",
    "document_id": "doc:ema.keytruda",
    "indication": "KEYTRUDA, in combination with fluoropyrimidine and platinum -containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-containing chemotherapy"
  },
  {
    "id": "ind:ema.kadcyla:0",
    "document_id": "doc:ema.kadcyla",
    "indication": "Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Kadcyla (trastuzumab emtansine)"
  },
  {
    "id": "ind:ema.kadcyla:1",
    "document_id": "doc:ema.kadcyla",
    "indication": "Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Kadcyla (trastuzumab emtansine)"
  },
  {
    "id": "ind:ema.kisqali:0",
    "document_id": "doc:ema.kisqali",
    "indication": "Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant"
  },
  {
    "id": "ind:ema.kisqali:1",
    "document_id": "doc:ema.kisqali",
    "indication": "Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.",
    "initial_approval_date": "2024-12-16",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/kisqali-h-c-004213-ii-0045-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.",
    "raw_biomarkers": "(HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor"
  },
  {
    "id": "ind:ema.krazati:0",
    "document_id": "doc:ema.krazati",
    "indication": "KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized adagrasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and disease progression after at least one prior systemic therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Krazati (adagrasib)"
  },
  {
    "id": "ind:ema.libtayo:0",
    "document_id": "doc:ema.libtayo",
    "indication": "LIBTAYO as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized cemiplimab as a monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Libtayo (cemiplimab)"
  },
  {
    "id": "ind:ema.libtayo:1",
    "document_id": "doc:ema.libtayo",
    "indication": "LIBTAYO in combination with platinum_based chemotherapy is indicated for the first_line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC. This indication is based on Study 16113, a randomized, multi-center, double-blind, active-controlled trial. The chemotherapy used in this study consisted of either carboplatin or cisplatin in combination with paclitaxel or pemetrexed.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Libtayo (cemiplimab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.lorviqua:0",
    "document_id": "doc:ema.lorviqua",
    "indication": "Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Lorviqua (lorlatinib)"
  },
  {
    "id": "ind:ema.lorviqua:1",
    "document_id": "doc:ema.lorviqua",
    "indication": "Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Lorviqua (lorlatinib)"
  },
  {
    "id": "ind:ema.lumykras:0",
    "document_id": "doc:ema.lumykras",
    "indication": "LUMYKRAS as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized sotorasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and who have progressed after at least one prior line of systemic therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Lumykras (sotorasib)"
  },
  {
    "id": "ind:ema.lynparza:0",
    "document_id": "doc:ema.lynparza",
    "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:1",
    "document_id": "doc:ema.lynparza",
    "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
    "raw_biomarkers": null,
    "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab"
  },
  {
    "id": "ind:ema.lynparza:2",
    "document_id": "doc:ema.lynparza",
    "indication": "Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:3",
    "document_id": "doc:ema.lynparza",
    "indication": "Lynparza is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.",
    "raw_biomarkers": null,
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:4",
    "document_id": "doc:ema.lynparza",
    "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Adenocarcinoma of the pancreas",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:5",
    "document_id": "doc:ema.lynparza",
    "indication": "Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Prostate cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:ema.lynparza:6",
    "document_id": "doc:ema.lynparza",
    "indication": "Lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Endometrial cancer",
    "raw_therapeutics": "Lynparza (olaparib) in combination with durvalumab for maintence treatment, after not progressing on first-line treatment with durvalumab in combination with carboplatin and paclitaxel"
  },
  {
    "id": "ind:ema.lytgobi:0",
    "document_id": "doc:ema.lytgobi",
    "indication": "Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cholangiocarcinoma",
    "raw_therapeutics": "Lytgobi (futibatinib)"
  },
  {
    "id": "ind:ema.mabthera:0",
    "document_id": "doc:ema.mabthera",
    "indication": "MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.",
    "raw_biomarkers": null,
    "raw_cancer_type": "diffuse large B cell non-Hodgkin's lymphoma",
    "raw_therapeutics": "MabThera (rituximab) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)"
  },
  {
    "id": "ind:ema.mabthera:1",
    "document_id": "doc:ema.mabthera",
    "indication": "MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL)",
    "raw_therapeutics": "MabThera (rituximab) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.mekinist:0",
    "document_id": "doc:ema.mekinist",
    "indication": "Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "trametinib as a monotherapy or in combination with dabrafenib"
  },
  {
    "id": "ind:ema.mekinist:1",
    "document_id": "doc:ema.mekinist",
    "indication": "Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:ema.mekinist:2",
    "document_id": "doc:ema.mekinist",
    "indication": "Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:ema.mektovi:0",
    "document_id": "doc:ema.mektovi",
    "indication": "Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib"
  },
  {
    "id": "ind:ema.mektovi:1",
    "document_id": "doc:ema.mektovi",
    "indication": "Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib"
  },
  {
    "id": "ind:ema.mylotarg:0",
    "document_id": "doc:ema.mylotarg",
    "indication": "MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized gemtuzumab ozogamicin in combination with cytarabine and daunorubicin for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukaemia (APL).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin (DNR) and cytarabine (AraC)"
  },
  {
    "id": "ind:ema.nerlynx:0",
    "document_id": "doc:ema.nerlynx",
    "indication": "Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib)"
  },
  {
    "id": "ind:ema.opdivo:0",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab and 2 cycles of platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.opdivo:1",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.opdivo:2",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nivolumab as a monotherapy for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC) with tumor cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Urothelial carcinoma",
    "raw_therapeutics": "Opdivo (nivolumab)"
  },
  {
    "id": "ind:ema.opdivo:3",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab"
  },
  {
    "id": "ind:ema.opdivo:4",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal squamous cell carcinoma",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab"
  },
  {
    "id": "ind:ema.opdivo:5",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable, advanced, or recurrent metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%. This indication is based on CA209648, a randomized, active-controlled, and open-label study where the choice of chemotherapy was fluorouracil and cisplatin.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal squamous cell carcinoma",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy"
  },
  {
    "id": "ind:ema.opdivo:6",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
    "raw_biomarkers": null,
    "raw_cancer_type": "gastric, gastro-oesophageal junction or oesophageal adenocarcinoma",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy"
  },
  {
    "id": "ind:ema.opdivo:7",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings: first-line treatment of unresectable or metastatic colorectal cancer; treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "initial_approval_date": "2025-01-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-ws-2672-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings: first-line treatment of unresectable or metastatic colorectal cancer; treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "raw_biomarkers": "mismatch repair deficient or microsatellite instability-high",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab"
  },
  {
    "id": "ind:ema.opdivo:8",
    "document_id": "doc:ema.opdivo",
    "indication": "OPDIVO in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by OPDIVO as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumors have PD-L1 expression >= 1%.",
    "initial_approval_date": "2025-06-02",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-003985-ii-0140-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment, followed by nivolumab as monotherapy as adjuvant treatment, of patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. This indication is based on CA20977T, randomised, double-blind study consisting of 461 patients. Platinum-based chemotherapy consisted of paclitaxel and carboplatin (any histology); pemetrexed and cisplatin (non-squamous histology); pemetrexed or carboplatin (non-squamous histology); or cisplatin and docetaxel (squamous histology).",
    "raw_biomarkers": "PD-L1 expression >= 1%",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.opdualag:0",
    "document_id": "doc:ema.opdualag",
    "indication": "Opdualag is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized Opdualag (relatlimab / nivolumab) for the first-line treatment of adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumor cell PD-L1 expression < 1%.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Opdualag (relatlimab / nivolumab)"
  },
  {
    "id": "ind:ema.orserdu:0",
    "document_id": "doc:ema.orserdu",
    "indication": "ORSERDU monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized elacestrant for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Orserdu (elacestrant)"
  },
  {
    "id": "ind:ema.pemazyre:0",
    "document_id": "doc:ema.pemazyre",
    "indication": "Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cholangiocarcinoma",
    "raw_therapeutics": "Orserdu (elacestrant)"
  },
  {
    "id": "ind:ema.perjeta:0",
    "document_id": "doc:ema.perjeta",
    "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:ema.perjeta:1",
    "document_id": "doc:ema.perjeta",
    "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:ema.perjeta:2",
    "document_id": "doc:ema.perjeta",
    "indication": "Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and docetaxel"
  },
  {
    "id": "ind:ema.phesgo:0",
    "document_id": "doc:ema.phesgo",
    "indication": "Phesgo is indicated for use in combination with chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.phesgo:1",
    "document_id": "doc:ema.phesgo",
    "indication": "Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.phesgo:2",
    "document_id": "doc:ema.phesgo",
    "indication": "Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with docetaxel"
  },
  {
    "id": "ind:ema.piqray:0",
    "document_id": "doc:ema.piqray",
    "indication": "Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Piqray (alpelisib) in combination with fulvestrant"
  },
  {
    "id": "ind:ema.retsevmo:0",
    "document_id": "doc:ema.retsevmo",
    "indication": "Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Retsevmo (selpercatinib)"
  },
  {
    "id": "ind:ema.retsevmo:1",
    "document_id": "doc:ema.retsevmo",
    "indication": "Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Thyroid cancer",
    "raw_therapeutics": "Retsevmo (selpercatinib)"
  },
  {
    "id": "ind:ema.retsevmo:2",
    "document_id": "doc:ema.retsevmo",
    "indication": "Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET-mutant medullary thyroid cancer. This indication is based on LIBRETTO-001 (a phase 1/2, multicenter, open-label, single-arm clinical study), where the most common variant was p.M918T, followed by extracelluar cysteine mutations.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Medullary thyroid cancer",
    "raw_therapeutics": "Retsevmo (selpercatinib)"
  },
  {
    "id": "ind:ema.retsevmo:3",
    "document_id": "doc:ema.retsevmo",
    "indication": "Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Retsevmo (selpercatinib)"
  },
  {
    "id": "ind:ema.revlimid:0",
    "document_id": "doc:ema.revlimid",
    "indication": "Revlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized lenalidomide for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermdeiate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.",
    "raw_biomarkers": null,
    "raw_cancer_type": "myelodysplastic syndromes",
    "raw_therapeutics": "Revlimid (lenalidomide)"
  },
  {
    "id": "ind:ema.rozlytrek:0",
    "document_id": "doc:ema.rozlytrek",
    "indication": "Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:ema.rozlytrek:1",
    "document_id": "doc:ema.rozlytrek",
    "indication": "Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, (iii) who have no satisfactory treatment options.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:ema.rydapt:0",
    "document_id": "doc:ema.rydapt",
    "indication": "Rydapt is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintence therapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. Midostaurin's product information further states that AML patients must have confirmation of the FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Rydapt (midostaurin)"
  },
  {
    "id": "ind:ema.scemblix:0",
    "document_id": "doc:ema.scemblix",
    "indication": "Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myeloid Leukemia",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:ema.spexotras:0",
    "document_id": "doc:ema.spexotras",
    "indication": "Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF p.V600E variant who require systemic therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "low-grade glioma",
    "raw_therapeutics": "Spexotras (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:ema.spexotras:1",
    "document_id": "doc:ema.spexotras",
    "indication": "Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF p.V600E variant who have received at least one prior radiation and/or chemotherapy treatment.",
    "raw_biomarkers": null,
    "raw_cancer_type": "high-grade glioma",
    "raw_therapeutics": "Spexotras (trametinib) in combination with dabrafenib"
  },
  {
    "id": "ind:ema.sprycel:0",
    "document_id": "doc:ema.sprycel",
    "indication": "SPRYCEL is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Sprycel (dasatinib [anhydrous])"
  },
  {
    "id": "ind:ema.sprycel:1",
    "document_id": "doc:ema.sprycel",
    "indication": "SPRYCEL is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML)",
    "raw_therapeutics": "Sprycel (dasatinib [anhydrous])"
  },
  {
    "id": "ind:ema.sprycel:2",
    "document_id": "doc:ema.sprycel",
    "indication": "SPRYCEL is indicated for the treatment of paediatric patients with newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase (Ph+ CML-CP) or Ph+CML-CP with resistant or intolerant to prior therapy including imatinib.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Sprycel (dasatinib [anhydrous])"
  },
  {
    "id": "ind:ema.sprycel:3",
    "document_id": "doc:ema.sprycel",
    "indication": "SPRYCEL is indicated for the treatment of paediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The product information for this indication further states that his indication is based on a multicenter, historically-controlled phase 2 study that followed the chemotherapy regime detailed in another clinical trial, AIEOP-BFM ALL 2000 (chemotherapeutic standard multi-agent chemotherapy protocol).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Sprycel (dasatinib [anhydrous]) in combination with chemotherapy"
  },
  {
    "id": "ind:ema.tabrecta:0",
    "document_id": "doc:ema.tabrecta",
    "indication": "Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tabrecta (capmatinib)"
  },
  {
    "id": "ind:ema.tafinlar:0",
    "document_id": "doc:ema.tafinlar",
    "indication": "Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib)"
  },
  {
    "id": "ind:ema.tafinlar:1",
    "document_id": "doc:ema.tafinlar",
    "indication": "Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib)"
  },
  {
    "id": "ind:ema.tafinlar:2",
    "document_id": "doc:ema.tafinlar",
    "indication": "Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tafinlar (dabrafenib)"
  },
  {
    "id": "ind:ema.tagrisso:0",
    "document_id": "doc:ema.tagrisso",
    "indication": "TAGRISSO as monotherapy is indicated for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:ema.tagrisso:1",
    "document_id": "doc:ema.tagrisso",
    "indication": "TAGRISSO as monotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized osimertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR variants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:ema.tagrisso:2",
    "document_id": "doc:ema.tagrisso",
    "indication": "TAGRISSO as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized osimertinib for treatment of adult patients with locally advanced or metastatic EGFR p.T790M mutation-positive non-small cell lung cancer.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:ema.tagrisso:3",
    "document_id": "doc:ema.tagrisso",
    "indication": "TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.tagrisso:4",
    "document_id": "doc:ema.tagrisso",
    "indication": "TAGRISSO as a monotherapy is indicated for the treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.",
    "initial_approval_date": "2025-01-09",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized osimertinib for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 (L858R)",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:ema.talzenna:0",
    "document_id": "doc:ema.talzenna",
    "indication": "Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Talzenna (talazoparib)"
  },
  {
    "id": "ind:ema.tarceva:0",
    "document_id": "doc:ema.tarceva",
    "indication": "Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized erlotinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating variants. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tarceva (erlotinib)"
  },
  {
    "id": "ind:ema.tarceva:1",
    "document_id": "doc:ema.tarceva",
    "indication": "Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized erlotinib for switch maintenance treatemnt of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating variants and stable disease after first-line chemotherapy. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tarceva (erlotinib)"
  },
  {
    "id": "ind:ema.tasigna:0",
    "document_id": "doc:ema.tasigna",
    "indication": "Tasigna is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (CML) in the chronic phase.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:ema.tasigna:1",
    "document_id": "doc:ema.tasigna",
    "indication": "Tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Nilotinib's product information further states that efficacy data in patients with CML in blast crisis are not available.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:ema.tasigna:2",
    "document_id": "doc:ema.tasigna",
    "indication": "Tasigna is indicated for the treatment of paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of pediatric patients with chronic phase Phildelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic Myelogenous Leukemia",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:ema.tecentriq:0",
    "document_id": "doc:ema.tecentriq",
    "indication": "Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC (i) after prior platinum-containing chemotherapy, or (ii) who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression >= 5%.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible, and whose tumors have PD-L1 expression >= 5%.",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:ema.tecentriq:1",
    "document_id": "doc:ema.tecentriq",
    "indication": "Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the adjuvant treatment following complete resection and platinum-based chemotherapy of adult patients with non-small cell lung cancer with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:ema.tecentriq:2",
    "document_id": "doc:ema.tecentriq",
    "indication": "Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin"
  },
  {
    "id": "ind:ema.tecentriq:3",
    "document_id": "doc:ema.tecentriq",
    "indication": "Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with nab-paclitaxel and carboplatin"
  },
  {
    "id": "ind:ema.tecentriq:4",
    "document_id": "doc:ema.tecentriq",
    "indication": "Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression >= 50% TC or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:ema.tecentriq:5",
    "document_id": "doc:ema.tecentriq",
    "indication": "Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:ema.tecentriq:6",
    "document_id": "doc:ema.tecentriq",
    "indication": "Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Triple-negative breast cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab) in combination with nab-paclitaxel"
  },
  {
    "id": "ind:ema.tepmetko:0",
    "document_id": "doc:ema.tepmetko",
    "indication": "TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tepmetko (tepotinib)"
  },
  {
    "id": "ind:ema.tibsovo:0",
    "document_id": "doc:ema.tibsovo",
    "indication": "Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine"
  },
  {
    "id": "ind:ema.tibsovo:1",
    "document_id": "doc:ema.tibsovo",
    "indication": "Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Cholangiocarcinoma",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:ema.tremelimumab-astrazeneca:0",
    "document_id": "doc:ema.tremelimumab-astrazeneca",
    "indication": "Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy",
    "status": "Withdrawn"
  },
  {
    "id": "ind:ema.trisenox:0",
    "document_id": "doc:ema.trisenox",
    "indication": "RISENOX is indicated for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized arsenic trioxide for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.",
    "raw_biomarkers": null,
    "raw_cancer_type": "acute promyelocytic leukaemia",
    "raw_therapeutics": "Trisenox (arsenic trioxide)"
  },
  {
    "id": "ind:ema.trodelvy:0",
    "document_id": "doc:ema.trodelvy",
    "indication": "Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",
    "raw_biomarkers": null,
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:ema.trodelvy:1",
    "document_id": "doc:ema.trodelvy",
    "indication": "Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:ema.tukysa:0",
    "document_id": "doc:ema.tukysa",
    "indication": "TUKYSA is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have at least 2 prior anti-HER2 treatment regimens.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Tukysa (tucatinib) in combination with trastuzumab and capecitabine"
  },
  {
    "id": "ind:ema.tyverb:0",
    "document_id": "doc:ema.tyverb",
    "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Tyverb (lapatinib) in combination with capecitabine"
  },
  {
    "id": "ind:ema.tyverb:1",
    "document_id": "doc:ema.tyverb",
    "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Tyverb (lapatinib) in combination with trastuzumab and chemotherapy"
  },
  {
    "id": "ind:ema.tyverb:2",
    "document_id": "doc:ema.tyverb",
    "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Tyverb (lapatinib) in combination with an aromataste inhibitor"
  },
  {
    "id": "ind:ema.vectibix:0",
    "document_id": "doc:ema.vectibix",
    "indication": "Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:ema.vectibix:1",
    "document_id": "doc:ema.vectibix",
    "indication": "Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFIRI for the second-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:ema.vectibix:2",
    "document_id": "doc:ema.vectibix",
    "indication": "Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized panitumumab as a monotherapy for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:ema.venclyxto:0",
    "document_id": "doc:ema.venclyxto",
    "indication": "Venclyxto monotherapy is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Venclyxto (venetoclax)"
  },
  {
    "id": "ind:ema.venclyxto:1",
    "document_id": "doc:ema.venclyxto",
    "indication": "Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed chemoimmunotherapy and a B-cell receptor pathway inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Venclyxto (venetoclax)"
  },
  {
    "id": "ind:ema.verzenios:0",
    "document_id": "doc:ema.verzenios",
    "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Breast cancer",
    "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy"
  },
  {
    "id": "ind:ema.verzenios:1",
    "document_id": "doc:ema.verzenios",
    "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy"
  },
  {
    "id": "ind:ema.vitrakvi:0",
    "document_id": "doc:ema.vitrakvi",
    "indication": "VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Any solid tumor",
    "raw_therapeutics": "Vitrakvi (larotrectinib)"
  },
  {
    "id": "ind:ema.vizimpro:0",
    "document_id": "doc:ema.vizimpro",
    "indication": "Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized dacomitinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating variants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Vizimpro (dacomitinib)"
  },
  {
    "id": "ind:ema.xalkori:0",
    "document_id": "doc:ema.xalkori",
    "indication": "XALKORI as monotherapy is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xalkori:1",
    "document_id": "doc:ema.xalkori",
    "indication": "XALKORI as monotherapy is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xalkori:2",
    "document_id": "doc:ema.xalkori",
    "indication": "XALKORI as monotherapy is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xalkori:3",
    "document_id": "doc:ema.xalkori",
    "indication": "XALKORI as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).",
    "raw_biomarkers": null,
    "raw_cancer_type": "anaplastic large cell lymphoma",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xalkori:4",
    "document_id": "doc:ema.xalkori",
    "indication": "XALKORI as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumour (IMT).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumor (IMT).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Inflammatory myofibroblastic tumour (IMT)",
    "raw_therapeutics": "Xalkori (crizotinib)"
  },
  {
    "id": "ind:ema.xospata:0",
    "document_id": "doc:ema.xospata",
    "indication": "Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Acute myeloid leukaemia",
    "raw_therapeutics": "Xospata (gilteritinib)"
  },
  {
    "id": "ind:ema.yervoy:0",
    "document_id": "doc:ema.yervoy",
    "indication": "YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.yervoy:1",
    "document_id": "doc:ema.yervoy",
    "indication": "YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Colorectal cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab"
  },
  {
    "id": "ind:ema.yervoy:2",
    "document_id": "doc:ema.yervoy",
    "indication": "YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Oesophageal squamous cell carcinoma",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab"
  },
  {
    "id": "ind:ema.yervoy:3",
    "document_id": "doc:ema.yervoy",
    "indication": "YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer.",
    "initial_approval_date": "2025-01-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-ws2672-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer.",
    "raw_biomarkers": "mismatch repair deficient or microsatellite instability-high",
    "raw_cancer_type": "colorectal cancer",
    "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab"
  },
  {
    "id": "ind:ema.zelboraf:0",
    "document_id": "doc:ema.zelboraf",
    "indication": "Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF V600 mutation- positive unresectable or metastatic melanoma.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Melanoma",
    "raw_therapeutics": "Zelboraf (vemurafenib)"
  },
  {
    "id": "ind:ema.zydelig:0",
    "document_id": "doc:ema.zydelig",
    "indication": "Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)",
    "raw_therapeutics": "Zydelig (idelalisib) in combination with rituximab"
  },
  {
    "id": "ind:ema.zykadia:0",
    "document_id": "doc:ema.zykadia",
    "indication": "Zykadia as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ceritinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:ema.zykadia:1",
    "document_id": "doc:ema.zykadia",
    "indication": "Zykadia as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized ceritinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:ema.tevimbra:0",
    "document_id": "doc:ema.tevimbra",
    "indication": "Tevimbra in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous NSCLC whose tumors have PD-L1 expression on >= 50% of tumor cells with no EGFR or ALK positive mutations and who have (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Tevimbra (tislelizumab) in combination with pemetrexed and platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.tevimbra:1",
    "document_id": "doc:ema.tevimbra",
    "indication": "Tevimbra, in combination with platinum-based chemotherapy, is indicated for the first-line treatment of adult patients with unresectable, locally advanced or metastatic OSCC whose tumours express PD-L1 with a TAP score >= 5%.",
    "initial_approval_date": "2024-12-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tevimbra-h-c-005919-ii-0003-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express PD-L1 with a tumor area positivity (TAP) score >= 5%. This indication is based on BGB-A317-306, a multi-regional, randomized, placebo-controlled, double-blind phase 3 study. The chemotherapy doublet regimen consisted of: cisplatin and 5-FU; cisplatin and capecitabine; oxaliplatin and 5-FU; oxaliplatin and capecitabine; cisplatin and paclitaxel; or oxaliplatin and paclitaxel.",
    "raw_biomarkers": "PD-L1 with a TAP score >= 5%",
    "raw_cancer_type": "Oesophageal squamous cell carcinoma (OSCC)",
    "raw_therapeutics": "Tevimbra, in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:ema.tevimbra:2",
    "document_id": "doc:ema.tevimbra",
    "indication": "Tevimbra, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumours express PD-L1 with a tumour area positivity (TAP) score >= 5%.",
    "initial_approval_date": "2024-12-19",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/tevimbra-h-c-005919-ii-0006-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with platinum and fluoropyrimidine-based chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 with a tumor area positivity (TAP) score >= 5%. This indication is based on BGB-A317-305, a global, randomized, double-blind, placebo-controlled study involving 997 patients. The chemotherapy regimen consisted of either oxaliplatin and capecitabine, or cisplatin and 5-FU.",
    "raw_biomarkers": "PD-L1 with a TAP score >= 5%",
    "raw_cancer_type": "gastric or gastroesophageal junction",
    "raw_therapeutics": "Tevimbra in combination with platinum and fluoropyrimidine-based chemotherapy"
  },
  {
    "id": "ind:ema.rybrevant:0",
    "document_id": "doc:ema.rybrevant",
    "indication": "Rybrevant is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab) in combination with carboplatin and pemetrexed"
  },
  {
    "id": "ind:ema.rybrevant:1",
    "document_id": "doc:ema.rybrevant",
    "indication": "Rybrevant is indicated as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized amivantamab as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.",
    "raw_biomarkers": null,
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab)"
  },
  {
    "id": "ind:ema.rybrevant:2",
    "document_id": "doc:ema.rybrevant",
    "indication": "Rybrevant is indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).",
    "initial_approval_date": "2024-09-13",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/rybrevant-h-c-005454-ii-0011-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).",
    "raw_biomarkers": "EGFR Exon 19 deletions or Exon 21 L858R",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab) in combination with carboplatin and pemetrexed"
  },
  {
    "id": "ind:ema.rybrevant:3",
    "document_id": "doc:ema.rybrevant",
    "indication": "Rybrevant is indicated in combination with lazertinib for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations.",
    "initial_approval_date": "2025-03-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/rybrevant-h-c-005454-ii-0013-epar-assessment-report-variation_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized amivantamab combination with lazertinib for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations.",
    "raw_biomarkers": "EGFR Exon 19 deletions or Exon 21 L858R",
    "raw_cancer_type": "Non-small cell lung cancer",
    "raw_therapeutics": "Rybrevant (amivantamab) in combination with lazertinib"
  },
  {
    "id": "ind:ema.truqap:0",
    "document_id": "doc:ema.truqap",
    "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
    "raw_biomarkers": null,
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant"
  },
  {
    "id": "ind:ema.balversa:0",
    "document_id": "doc:ema.balversa",
    "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
    "raw_biomarkers": null,
    "raw_cancer_type": "urothelial carcinoma",
    "raw_therapeutics": "Balversa (erdafitinib)"
  },
  {
    "id": "ind:ema.vyloy:0",
    "document_id": "doc:ema.vyloy",
    "indication": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",
    "raw_biomarkers": null,
    "raw_cancer_type": "Gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy"
  },
  {
    "id": "ind:ema.augtyro:0",
    "document_id": "doc:ema.augtyro",
    "indication": "AUGTYRO as monotherapy is indicated for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)",
    "initial_approval_date": "2025-01-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/augtyro-epar-public-assessment-report_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized repotrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Augtyro (repotrectinib)"
  },
  {
    "id": "ind:ema.augtyro:1",
    "document_id": "doc:ema.augtyro",
    "indication": "AUGTYRO as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with advanced solid tumors expression NTRK gene fusions, and (i) who have received a prior NTRK inhibitor, or (ii) have not received a prior NTRK inhibitor and treatment options not targeting NTRK provide limited clinial benefit, or have been exhausted.",
    "initial_approval_date": "2025-01-28",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/augtyro-epar-public-assessment-report_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized repotrectinib for the treatment of adult and pediatric patients 12 years of age and older with advanced solid tumors expression NTRK gene fusions, and (i) who have received a prior NTRK inhibitor, or (ii) have not received a prior NTRK inhibitor and treatment options not targeting NTRK provide limited clinial benefit, or have been exhausted.",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Augtyro (repotrectinib)"
  },
  {
    "id": "ind:ema.lazcluze:0",
    "document_id": "doc:ema.lazcluze",
    "indication": "Lazcluze in combination with amivantamab is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.",
    "initial_approval_date": "2025-03-17",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/lazcluze-epar-public-assessment-report_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized lazertinib in combination with amivantamab is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "non-small cell lung cancer",
    "raw_therapeutics": "Lazcluze (lazertinib) in combination with amivantamab"
  },
  {
    "id": "ind:ema.elahere:0",
    "document_id": "doc:ema.elahere",
    "indication": "ELAHERE as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FDalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.",
    "initial_approval_date": "2024-12-11",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/elahere-epar-public-assessment-report_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized mirvetuximab soravtansine for the treatment of adult patients with with folate receptor-alpha (FDalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.",
    "raw_biomarkers": "folate receptor-alpha (FDalpha) positive",
    "raw_cancer_type": "high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer",
    "raw_therapeutics": "mirvetuximab soravtansine"
  },
  {
    "id": "ind:ema.itovebi:0",
    "document_id": "doc:ema.itovebi",
    "indication": "Itovebi, in combination with palbocicliab and fulvestrant, is indicated for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. Patients previously treated with a CDK 4/6 inhibitor in the (neo)adjuvant setting should have had an interval of at least 12 months between termination of CDK 4/6 inhibitor treatment and the detection of recurrence. In pre/perimenopausal women and in men, endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.",
    "initial_approval_date": "2025-08-27",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/itovebi-epar-public-assessment-report_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized inavolisib in combination with palbocicliab and fulvestrant for the treatment of adult patients with PIK3CA-mutated, estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. Patients previously treated with a CDK 4/6 inhibitor in the (neo)adjuvant setting should have had an interval of at least 12 months between termination of CDK 4/6 inhibitor treatment and the detection of recurrence. In pre/perimenopausal women and in men, endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.",
    "raw_biomarkers": "PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative",
    "raw_cancer_type": "breast cancer",
    "raw_therapeutics": "inavolisib in combination with palbocicliab and fulvestrant"
  },
  {
    "id": "ind:ema.ziihera:0",
    "document_id": "doc:ema.ziihera",
    "indication": "Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.",
    "initial_approval_date": "2025-07-03",
    "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/ziihera-epar-public-assessment-report_en.pdf",
    "description": "The European Medicines Agency (EMA) has authorized zanidatamab for the treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.",
    "raw_biomarkers": "HER2-positive (IHC3+)",
    "raw_cancer_type": "biliary tract cancer (BTC)",
    "raw_therapeutics": "Ziihera (zanidatamab)"
  },
  {
    "id": "ind:hc.adcetris:0",
    "document_id": "doc:hc.adcetris",
    "indication": "ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.",
    "raw_biomarkers": "CD30-expressing",
    "raw_cancer_type": "systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)"
  },
  {
    "id": "ind:hc.adcetris:1",
    "document_id": "doc:hc.adcetris",
    "indication": "ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.",
    "raw_biomarkers": "CD30-expressing",
    "raw_cancer_type": "CD30-Expressing Mycosis Fungoides (MF)",
    "raw_therapeutics": "Adcetris (brentuximab vedotin)"
  },
  {
    "id": "ind:hc.afinitor:0",
    "document_id": "doc:hc.afinitor",
    "indication": "AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced breast cancer",
    "raw_therapeutics": "Afinitor (everolimus) in combination with exemestane"
  },
  {
    "id": "ind:hc.akeega:0",
    "document_id": "doc:hc.akeega",
    "indication": "AKEEGA (niraparib and abiraterone acetate) is indicated with prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC), who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved niraparib and abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (mCRPC), who are asymptomatic or mildly symptomatic, and in whom chemotherapy is not clinically indicated.",
    "raw_biomarkers": "deleterious or suspected deleterious BRCA mutated (germline and/or somatic)",
    "raw_cancer_type": "metastatic castration resistant prostate cancer",
    "raw_therapeutics": "Akeega (niraparib and abiraterone acetate) with prednisone or prednisolone"
  },
  {
    "id": "ind:hc.alecensaro:0",
    "document_id": "doc:hc.alecensaro",
    "indication": "ALECENSARO (alectinib) is indicated for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved alectinib for the first-line treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Alecensaro (alectinib)"
  },
  {
    "id": "ind:hc.alunbrig:0",
    "document_id": "doc:hc.alunbrig",
    "indication": "ALUNBRIG (brigatinib) is indicated as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved brigatinib as monotherapy for the first-line treatment of adult patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Alunbrig (brigatinib)"
  },
  {
    "id": "ind:hc.augtyro:0",
    "document_id": "doc:hc.augtyro",
    "indication": "AUGTYRO (repotrectinib capsules) is indicated for treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer",
    "raw_therapeutics": "Augtyro (repotrectinib)"
  },
  {
    "id": "ind:hc.balversa:0",
    "document_id": "doc:hc.balversa",
    "indication": "BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.",
    "raw_biomarkers": "susceptible FGFR3 genetic alterations",
    "raw_cancer_type": "locally advanced unresectable or metastatic urothelial carcinoman (UC)",
    "raw_therapeutics": "Balversa (erdafitinib)"
  },
  {
    "id": "ind:hc.besponsa:0",
    "document_id": "doc:hc.besponsa",
    "indication": "BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).",
    "raw_biomarkers": "CD22-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia",
    "raw_therapeutics": "Besponsa (inotuzumab ozogamicin)"
  },
  {
    "id": "ind:hc.blincyto:0",
    "document_id": "doc:hc.blincyto",
    "indication": "BLINCYTO (blinatumomab for injection) is indicated for the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved blinatumomab for the treatment of patients with Philadelphia chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.",
    "raw_biomarkers": "philadelphia chromosone-negative, CD19-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:hc.blincyto:1",
    "document_id": "doc:hc.blincyto",
    "indication": "BLINCYTO (blinatumomab for injection) is indicated for the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or second hematologic complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved blinatumomab for the treatment of patients with Philadelphia chromosome-negative CD19-positive B-cell precursor ALL in first or second hematologic complete remission with minimal residual disease (MRD) \u2265 0.1%, as determined by an accredited laboratory using validated assay methods.",
    "raw_biomarkers": "philadelphia chromosome-negative, CD19-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:hc.blincyto:2",
    "document_id": "doc:hc.blincyto",
    "indication": "BLINCYTO (blinatumomab for injection) is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved blinatumomab for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).",
    "raw_biomarkers": "CD19-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:hc.blincyto:3",
    "document_id": "doc:hc.blincyto",
    "indication": "BLINCYTO (blinatumomab for injection) is indicated for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved blinatumomab for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).",
    "raw_biomarkers": "philadelphia chromosome-negative, CD19-positive",
    "raw_cancer_type": "B-cell precursor acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Blincyto (blinatumomab)"
  },
  {
    "id": "ind:hc.bosulif:0",
    "document_id": "doc:hc.bosulif",
    "indication": "BOSULIF (bosutinib) is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved bosutinib for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myelogenous leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:hc.bosulif:1",
    "document_id": "doc:hc.bosulif",
    "indication": "BOSULIF (bosutinib) is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved bosutinib for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.",
    "raw_biomarkers": "philadelphia chromosone-positive (Ph+)",
    "raw_cancer_type": "chronic myelogenous leukemia",
    "raw_therapeutics": "Bosulif (bosutinib)"
  },
  {
    "id": "ind:hc.braftovi:0",
    "document_id": "doc:hc.braftovi",
    "indication": "BRAFTOVI (encorafenib) is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved encorafenib in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",
    "raw_biomarkers": "BRAF V600E or BRAF V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib"
  },
  {
    "id": "ind:hc.braftovi:1",
    "document_id": "doc:hc.braftovi",
    "indication": "BRAFTOVI (encorafenib) is indicated, in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved encorafenib in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic colorectal cancer (mCRC)",
    "raw_therapeutics": "Braftovi (encorafenib) in combination with cetuximab"
  },
  {
    "id": "ind:hc.cotellic:0",
    "document_id": "doc:hc.cotellic",
    "indication": "COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "raw_biomarkers": "BRAF V600 mutation",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Cotellic in combination with vemurafenib"
  },
  {
    "id": "ind:hc.enhertu:0",
    "document_id": "doc:hc.enhertu",
    "indication": "ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:hc.enhertu:1",
    "document_id": "doc:hc.enhertu",
    "indication": "ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:hc.enhertu:2",
    "document_id": "doc:hc.enhertu",
    "indication": "ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab deruxtecan as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.",
    "raw_biomarkers": "HER2-low (IHC 1+ or IHC 2+/ISH-)",
    "raw_cancer_type": "unresectable or metastatic breast cancer",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:hc.enhertu:3",
    "document_id": "doc:hc.enhertu",
    "indication": "ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable,locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)"
  },
  {
    "id": "ind:hc.erbitux:0",
    "document_id": "doc:hc.erbitux",
    "indication": "ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.",
    "raw_biomarkers": "EGFR-expressing, K-Ras wild type",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin)"
  },
  {
    "id": "ind:hc.erbitux:1",
    "document_id": "doc:hc.erbitux",
    "indication": "ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.",
    "raw_biomarkers": "EGFR-expressing, K-Ras wild type",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Erbitux (cetuximab) in combination with irinotecan"
  },
  {
    "id": "ind:hc.erbitux:2",
    "document_id": "doc:hc.erbitux",
    "indication": "ERBITUX (cetuximab) is indicated as a single agent in patients who are intolerant to irinotecan-based chemotherapy for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who are intolerant to irinotecan-based chemotherapy.",
    "raw_biomarkers": "EGFR-expressing, K-Ras wild type",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Erbitux (cetuximab) as a single agent"
  },
  {
    "id": "ind:hc.erbitux:3",
    "document_id": "doc:hc.erbitux",
    "indication": "ERBITUX (cetuximab) is indicated as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.",
    "raw_biomarkers": "EGFR-expressing, K-Ras wild type",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Erbitux (cetuximab) as a single agent"
  },
  {
    "id": "ind:hc.faslodex:0",
    "document_id": "doc:hc.faslodex",
    "indication": "FASLODEX (fulvestrant) is indicated for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved fulvestrant for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.",
    "raw_biomarkers": "estrogen receptor-positive (ER+), HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Faslodex (fulvestrant)"
  },
  {
    "id": "ind:hc.giotrif:0",
    "document_id": "doc:hc.giotrif",
    "indication": "GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor na\u00efve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor na\u00efve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).",
    "raw_biomarkers": "EGFR Del 19, EGFR exon 21 L858R",
    "raw_cancer_type": "metastatic adenocarcinoma of the lung",
    "raw_therapeutics": "Giotrif (afatinib)"
  },
  {
    "id": "ind:hc.gleevec:0",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.",
    "raw_biomarkers": "philadelphia chromosome-positive",
    "raw_cancer_type": "chronic myeloid leukemia",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:1",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:2",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate ",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "acute lymphoblastic leukemia",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:3",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.",
    "raw_biomarkers": "Philadelphia chromosome-positive",
    "raw_cancer_type": "acute lymphoblastic leukemia (Ph+ALL)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:4",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.",
    "raw_biomarkers": "DGFR gene re-arrangements",
    "raw_cancer_type": "myelodysplastic/myeloproliferative diseases (MDS/MPD)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:5",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.",
    "raw_biomarkers": "without D816V c-Kit mutation or with the c-Kit mutational status unknown",
    "raw_cancer_type": "systemic mastocytosis (ASM and SMAHNMD)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:6",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR\u03b1 rearrangement.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR\u03b1 rearrangement.",
    "raw_biomarkers": "FIP1L1::PDGFRA rearrangement",
    "raw_cancer_type": "advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:7",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
    "raw_biomarkers": "Kit (CD117) positive",
    "raw_cancer_type": "unresectable and/or metastatic malignant gastrointestinal stromal tumors",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.gleevec:8",
    "document_id": "doc:hc.gleevec",
    "indication": "GLEEVEC (imatinib mesylate) is indicated for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved imatinib mesylate for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.",
    "raw_biomarkers": "Kit (CD117) positive",
    "raw_cancer_type": "gastrointestinal stromal tumors (GIST)",
    "raw_therapeutics": "Gleevec (imatinib mesylate)"
  },
  {
    "id": "ind:hc.herceptin:0",
    "document_id": "doc:hc.herceptin",
    "indication": "HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:hc.herceptin:1",
    "document_id": "doc:hc.herceptin",
    "indication": "HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab in combination with paclitaxel or docetaxel for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide.",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab), paclitaxel, docetaxel"
  },
  {
    "id": "ind:hc.herceptin:2",
    "document_id": "doc:hc.herceptin",
    "indication": "HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab in combination with docetaxel and carboplatin for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2.",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab), docetaxel, carboplatin"
  },
  {
    "id": "ind:hc.herceptin:3",
    "document_id": "doc:hc.herceptin",
    "indication": "HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with metastatic breast cancer (MBC) whose tumours overexpress HER2.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab for metastatic breast cancer in patients whose tumors overexpress HER2.",
    "raw_biomarkers": "HER2-overexpressing",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab)"
  },
  {
    "id": "ind:hc.herceptin:4",
    "document_id": "doc:hc.herceptin",
    "indication": "HERCEPTIN (trastuzumab for injection) can be used in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Herceptin (trastuzumab), pertuzumab, docetaxel"
  },
  {
    "id": "ind:hc.herceptin:5",
    "document_id": "doc:hc.herceptin",
    "indication": "HERCEPTIN (trastuzumab for injection) in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab in combination with capecitabine or intravenous 5-fluorouracil and cisplatin for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction in patients who have not received prior anti-cancer treatment for metastatic disease.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic adenocarcinoma of the stomach or gastro-esophageal junction",
    "raw_therapeutics": "Herceptin (trastuzumab), capecitabine, 5-fluorouracil, cisplatin"
  },
  {
    "id": "ind:hc.ibrance:0",
    "document_id": "doc:hc.ibrance",
    "indication": "IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib), aromatase inhibitor"
  },
  {
    "id": "ind:hc.ibrance:1",
    "document_id": "doc:hc.ibrance",
    "indication": "IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Ibrance (palbociclib), fulvestrant"
  },
  {
    "id": "ind:hc.iclusig:0",
    "document_id": "doc:hc.iclusig",
    "indication": "ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML that is T315I mutation positive or where there is prior TKI resistance or intolerance",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.",
    "raw_biomarkers": "T315I mutation positive",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:hc.iclusig:1",
    "document_id": "doc:hc.iclusig",
    "indication": "ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including Ph+ ALL that is T315I mutation positive or where there is prior TKI resistance or intolerance",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.",
    "raw_biomarkers": "Philadelphia chromosome positive, T315I mutation positive",
    "raw_cancer_type": "acute lymphoblastic leukemia (Ph+ ALL)",
    "raw_therapeutics": "Iclusig (ponatinib)"
  },
  {
    "id": "ind:hc.imfinzi:0",
    "document_id": "doc:hc.imfinzi",
    "indication": "IMFINZI (durvalumab) in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.",
    "raw_biomarkers": "no sensitizing EGFR mutations or ALK genomic aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer",
    "raw_therapeutics": "Imfinzi (durvalumab), tremelimumab, platinum-based chemotherapy"
  },
  {
    "id": "ind:hc.imfinzi:1",
    "document_id": "doc:hc.imfinzi",
    "indication": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.",
    "raw_biomarkers": "mismatch repair deficient (dMMR)",
    "raw_cancer_type": "primary advanced or recurrent endometrial cancer",
    "raw_therapeutics": "Imfinzi (durvalumab), carboplatin, paclitaxel"
  },
  {
    "id": "ind:hc.iressa:0",
    "document_id": "doc:hc.iressa",
    "indication": "IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ",
    "raw_biomarkers": "activating mutations of EGFR",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Iressa (gefitinib)"
  },
  {
    "id": "ind:hc.itovebi:0",
    "document_id": "doc:hc.itovebi",
    "indication": "ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.",
    "raw_biomarkers": "PIK3CA-mutated, HR-positive, HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Itovebi (inavolisib), palbociclib, fulvestrant"
  },
  {
    "id": "ind:hc.jemperli:0",
    "document_id": "doc:hc.jemperli",
    "indication": "JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.",
    "raw_biomarkers": "mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H)",
    "raw_cancer_type": "recurrent or advanced endometrial cancer",
    "raw_therapeutics": "Jemperli (dostarlimab)"
  },
  {
    "id": "ind:hc.kadcyla:0",
    "document_id": "doc:hc.kadcyla",
    "indication": "KADCYLA (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Kadcyla (trastuzumab emtansine)"
  },
  {
    "id": "ind:hc.kadcyla:1",
    "document_id": "doc:hc.kadcyla",
    "indication": "KADCYLA monotherapy indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Kadcyla (trastuzumab emtansine)"
  },
  {
    "id": "ind:hc.keytruda:0",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab) is indicated for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.",
    "raw_biomarkers": "BRAF V600 mutation",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:1",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab) as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS) \u2265 1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS) \u2265 1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.",
    "raw_biomarkers": "PD-L1 (TPS \u2265 1%), EGFR genomic tumour aberrations, ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung carcinoma (NSCLC)",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:2",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, is indicated for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab in combination with pemetrexed and platinum chemotherapy for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.",
    "raw_biomarkers": "no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-squamous non-small cell lung carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab), pemetrexed, platinum chemotherapy"
  },
  {
    "id": "ind:hc.keytruda:3",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab) is indicated Keytruda as monotherapy is indicated for the treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS \u2265 1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab as a monotherapy for treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS \u2265 1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.",
    "raw_biomarkers": "PD-L1 (TPS \u2265 1%)",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:4",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "metastatic colorectal cancer (CRC)",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:5",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "",
    "raw_biomarkers": "MSI-H or dMMR ",
    "raw_cancer_type": "unresectable or metastatic MSI-H or dMMR solid tumors",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:6",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab), in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab in combination with lenvatinib for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.",
    "raw_biomarkers": "not MSI-H or dMMR",
    "raw_cancer_type": "advanced endometrial carcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab), lenvatinib"
  },
  {
    "id": "ind:hc.keytruda:7",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab) is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS] \u2265 1) as determined by a validated test.",
    "initial_approval_date": null,
    "initial_approval_url": " ",
    "description": "Health Canada approved pembrolizumab for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS] \u2265 1) as determined by a validated test.",
    "raw_biomarkers": "PD-L1 (CPS \u2265 1)",
    "raw_cancer_type": " metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC)",
    "raw_therapeutics": "Keytruda (pembrolizumab)"
  },
  {
    "id": "ind:hc.keytruda:8",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy,is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] \u22651) as determined by a validated test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] \u22651) as determined by a validated test.",
    "raw_biomarkers": "HER2-positive, PD-L1 (CPS \u2265 1)",
    "raw_cancer_type": " locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Keytruda (pembrolizumab), trastuzumab, fluoropyrimidine, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.keytruda:9",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.",
    "raw_biomarkers": "HER2-negative",
    "raw_cancer_type": " locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.",
    "raw_therapeutics": "Keytruda (pembrolizumab), fluoropyrimidine, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.keytruda:10",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab), in combination with chemotherapy, is indicated for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS] \u2265 10) as determined by a validated test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab, in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS] \u2265 10) as determined by a validated test.",
    "raw_biomarkers": "PD-L1 (CPS) >= 10",
    "raw_cancer_type": "locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)",
    "raw_therapeutics": "Keytruda (pembrolizumab), chemotherapy"
  },
  {
    "id": "ind:hc.keytruda:11",
    "document_id": "doc:hc.keytruda",
    "indication": "KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS \u2265 1) as determined by a validated test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS \u2265 1) as determined by a validated test.",
    "raw_biomarkers": "PD-L1 (CPS \u2265 1)",
    "raw_cancer_type": "persistent, recurrent, or metastatic cervical cancer",
    "raw_therapeutics": "Keytruda (pembrolizumab), chemotherapy, bevacizumab"
  },
  {
    "id": "ind:hc.kisqali:0",
    "document_id": "doc:hc.kisqali",
    "indication": "KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib), aromatase inhibitor"
  },
  {
    "id": "ind:hc.kisqali:1",
    "document_id": "doc:hc.kisqali",
    "indication": "KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.",
    "raw_biomarkers": "HR+, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Kisqali (ribociclib), fulvestrant"
  },
  {
    "id": "ind:hc.lazcluze:0",
    "document_id": "doc:hc.lazcluze",
    "indication": "LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Lazcluze (lazertinib), amivantamab"
  },
  {
    "id": "ind:hc.libtayo:0",
    "document_id": "doc:hc.libtayo",
    "indication": "LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in \u2265 50% of tumour cells (Tumour Proportion Score [TPS] \u2265 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in \u2265 50% of tumour cells (Tumour Proportion Score [TPS] \u2265 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",
    "raw_biomarkers": "PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations",
    "raw_cancer_type": "non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Libtayo (Cemiplimab)"
  },
  {
    "id": "ind:hc.libtayo:1",
    "document_id": "doc:hc.libtayo",
    "indication": "LIBTAYO (cemiplimab for injection) in combination with platinum\u2010based chemotherapy for the first\u2010line treatment of adult patients with NSCLC whose tumors have no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved cemiplimab in cominbation with platinum-based chemotherapy for the first\u2010line treatment of adult patients with NSCLC whose tumors have no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",
    "raw_biomarkers": "No EGFR, ALK, or ROS1 aberrations",
    "raw_cancer_type": "non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Libtayo (cemiplimab) in combination with platinum-based chemotherapy"
  },
  {
    "id": "ind:hc.lorbrena:0",
    "document_id": "doc:hc.lorbrena",
    "indication": "LORBRENA (lorlatinib) is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved lorlatinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Lorbrena (lorlatinib)"
  },
  {
    "id": "ind:hc.lorbrena:1",
    "document_id": "doc:hc.lorbrena",
    "indication": "LORBRENA (lorlatinib) is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved lorlatinib as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Lorbrena (lorlatinib)"
  },
  {
    "id": "ind:hc.lumakras:0",
    "document_id": "doc:hc.lumakras",
    "indication": "LUMAKRAS (sotorasib) is indicated for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved sotorasib for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.",
    "raw_biomarkers": "KRAS p.G12C",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Lumakras (sotorasib)"
  },
  {
    "id": "ind:hc.lynparza:0",
    "document_id": "doc:hc.lynparza",
    "indication": "LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm, HER2-negative",
    "raw_cancer_type": "high risk early breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:1",
    "document_id": "doc:hc.lynparza",
    "indication": "LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.",
    "raw_biomarkers": "deleterious or suspected deleterious gBRCAm, HER2-negative",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:2",
    "document_id": "doc:hc.lynparza",
    "indication": "LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.",
    "raw_biomarkers": "BRCA-mutated",
    "raw_cancer_type": "advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:3",
    "document_id": "doc:hc.lynparza",
    "indication": "LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.",
    "raw_biomarkers": "HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability",
    "raw_cancer_type": "advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",
    "raw_therapeutics": "Lynparza (olaparib), bevacizumab"
  },
  {
    "id": "ind:hc.lynparza:4",
    "document_id": "doc:hc.lynparza",
    "indication": "LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.",
    "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated (gBRCAm)",
    "raw_cancer_type": "metastatic adenocarcinoma of the pancreas",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:5",
    "document_id": "doc:hc.lynparza",
    "indication": "LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.",
    "raw_biomarkers": "deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation",
    "raw_cancer_type": " metastatic castrationresistant Prostate Cancer (mCRPC)",
    "raw_therapeutics": "Lynparza (olaparib)"
  },
  {
    "id": "ind:hc.lynparza:6",
    "document_id": "doc:hc.lynparza",
    "indication": "LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.",
    "raw_biomarkers": "germline and/or somatic BRCA mutation",
    "raw_cancer_type": "metastatic castration-resistant prostate cancer (mCRPC)",
    "raw_therapeutics": "Lynparza (olaparib), abiraterone, prednisone or prednisolone"
  },
  {
    "id": "ind:hc.mekinist:0",
    "document_id": "doc:hc.mekinist",
    "indication": "MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.",
    "raw_biomarkers": "BRAF V600E or V600K mutation",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Mekinist (trametinib) monotherapy or dabrafenib"
  },
  {
    "id": "ind:hc.mekinist:1",
    "document_id": "doc:hc.mekinist",
    "indication": "MEKINIST (trametinib), in combination with dabrafenib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph nodes, following complete resection.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trametinib in combination with dabrafenib for the adjuvant treatment of patients with BRAF V600E or V600K-mutant melanoma and lymph node involvement after complete resection.",
    "raw_biomarkers": "BRAF V600E or V600K mutation",
    "raw_cancer_type": "melanoma",
    "raw_therapeutics": "Mekinist (trametinib), dabrafenib"
  },
  {
    "id": "ind:hc.mekinist:2",
    "document_id": "doc:hc.mekinist",
    "indication": "MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trametinib in combination with dabrafenib for the treatment of patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": "BRAF V600E mutation",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Mekinist (trametinib), dabrafenib"
  },
  {
    "id": "ind:hc.mekinist:3",
    "document_id": "doc:hc.mekinist",
    "indication": "MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trametinib in combination with dabrafenib for the treatment of pediatric patients 1 year of age and older with BRAF V600E-mutant low-grade glioma (LGG) requiring systemic therapy.",
    "raw_biomarkers": "BRAF V600E mutation",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "Mekinist (trametinib), dabrafenib"
  },
  {
    "id": "ind:hc.mekinist:4",
    "document_id": "doc:hc.mekinist",
    "indication": "MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved trametinib in combination with dabrafenib for the treatment of pediatric patients 1 year of age and older with BRAF V600E-mutant high-grade glioma (HGG) who have received prior radiation and/or chemotherapy.",
    "raw_biomarkers": "BRAF V600E mutation",
    "raw_cancer_type": "high-grade glioma (HGG)",
    "raw_therapeutics": "Mekinist (trametinib), dabrafenib"
  },
  {
    "id": "ind:hc.mektovi:0",
    "document_id": "doc:hc.mektovi",
    "indication": "MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "unresectable or metastatic melanoma ",
    "raw_therapeutics": "Mektovi (binimetinib), encorafenib"
  },
  {
    "id": "ind:hc.mylotarg:0",
    "document_id": "doc:hc.mylotarg",
    "indication": "Mylotarg (gemtuzumab ozogamicin for injection) is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved gemtuzumab ozogamicin  in combination with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.",
    "raw_biomarkers": "CD33-positive",
    "raw_cancer_type": "acute myeloid leukeia (AML)",
    "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin), daunorubicin (DNR), cytarabine (AraC)"
  },
  {
    "id": "ind:hc.nerlynx:0",
    "document_id": "doc:hc.nerlynx",
    "indication": "NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.",
    "raw_biomarkers": "HR+, HER2-overexpressed/amplified",
    "raw_cancer_type": "early-stage breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib)"
  },
  {
    "id": "ind:hc.nerlynx:1",
    "document_id": "doc:hc.nerlynx",
    "indication": "NERLYNX (neratinib) is indicated in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved neratinib in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.",
    "raw_biomarkers": "HER2-overexpressed/amplified",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Nerlynx (neratinib), capecitabine"
  },
  {
    "id": "ind:hc.opdivo:0",
    "document_id": "doc:hc.opdivo",
    "indication": "OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nivolumab for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.",
    "raw_biomarkers": "BRAF V600 mutation-positive,",
    "raw_cancer_type": " unresectable or metastatic melanoma",
    "raw_therapeutics": "Opdivo (nivolumab)"
  },
  {
    "id": "ind:hc.opdivo:1",
    "document_id": "doc:hc.opdivo",
    "indication": "OPDIVO, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving OPDIVO.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nivolumab as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving OPDIVO.",
    "raw_biomarkers": "EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": " locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Opdivo (nivolumab)"
  },
  {
    "id": "ind:hc.opdivo:2",
    "document_id": "doc:hc.opdivo",
    "indication": "OPDIVO (nivolumab) in combination with ipilimumab, is indicated for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 \u2265 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nivolumab in combination with ipilimumab, for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 \u2265 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",
    "raw_biomarkers": " PD-L1 \u2265 1% with no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Opdivo (nivolumab), ipilimumab"
  },
  {
    "id": "ind:hc.opdivo:3",
    "document_id": "doc:hc.opdivo",
    "indication": "OPDIVO (nivolumab), in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nivolumab in combinatiom with ipilimumab and 2 cycles of platinum-doublet chemotherapy, for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",
    "raw_biomarkers": "no EGFR or ALK tumour genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Opdivo (nivolumab), ipilimumab, 2 cycles of platinum-doublet chemotherapy"
  },
  {
    "id": "ind:hc.opdivo:4",
    "document_id": "doc:hc.opdivo",
    "indication": "OPDIVO (nivolumab), in combination with ipilimumab, is indicated for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nivolumab, in combination with ipilimumab, for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal caner after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.",
    "raw_biomarkers": "MSI-H or dMMR",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Opdivo (nivolumab), ipilimumab"
  },
  {
    "id": "ind:hc.opdivo:5",
    "document_id": "doc:hc.opdivo",
    "indication": "OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with HER2 negative advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with HER2 negative advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.",
    "raw_biomarkers": "HER2-negative",
    "raw_cancer_type": "negative advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma",
    "raw_therapeutics": "Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.opdivo:6",
    "document_id": "doc:hc.opdivo",
    "indication": "OPDIVO (nivolumab), in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression \u2265 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nivolumab, in combination with ipilimuab, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression \u2265 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",
    "raw_biomarkers": "PD-L1 \u2265 1%",
    "raw_cancer_type": "unresectable or metastatic esophageal squamous cell carcinoma (ESCC)",
    "raw_therapeutics": "Opdivo (nivolumab), ipilimumab"
  },
  {
    "id": "ind:hc.opdivo:7",
    "document_id": "doc:hc.opdivo",
    "indication": "OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression \u2265 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression \u2265 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",
    "raw_biomarkers": "PD-L1 \u2265 1%",
    "raw_cancer_type": "unresectable or metastatic esophageal squamous cell carcinoma (ESCC)",
    "raw_therapeutics": "Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.pemazyre:0",
    "document_id": "doc:hc.pemazyre",
    "indication": "PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.",
    "raw_biomarkers": "FGFR2 fusion or rearrangement",
    "raw_cancer_type": "unresectable locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Pemazyre (pemigatinib)"
  },
  {
    "id": "ind:hc.perjeta:0",
    "document_id": "doc:hc.perjeta",
    "indication": "PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "early stage breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab), trastuzumab, chemotherapy"
  },
  {
    "id": "ind:hc.perjeta:1",
    "document_id": "doc:hc.perjeta",
    "indication": "PERJETA (pertuzumab) is indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pertuzumab in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Perjeta (pertuzumab), trastuzumab, docetaxel"
  },
  {
    "id": "ind:hc.phesgo:0",
    "document_id": "doc:hc.phesgo",
    "indication": "PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "locally advanced, inflammatory, or early stage breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab), chemotherapy"
  },
  {
    "id": "ind:hc.phesgo:1",
    "document_id": "doc:hc.phesgo",
    "indication": "PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer with lymph node positive and/or hormone receptor negative disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the adjuvant treatment of patients with HER2-poitive early breast cancer with lymph node positive and/hormone receptor negative disease.",
    "raw_biomarkers": "HR-negative, HER2-positive",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab), chemotherapy"
  },
  {
    "id": "ind:hc.phesgo:2",
    "document_id": "doc:hc.phesgo",
    "indication": "PHESGO (pertuzumab and trastuzumab), is indicated in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved pertuzumab and trastuzumab in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anit-HER2 therapy or chemotherapy for metastatic disease.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Phesgo (pertuzumab and trastuzumab), docetaxel"
  },
  {
    "id": "ind:hc.piqray:0",
    "document_id": "doc:hc.piqray",
    "indication": "PIQRAY (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.",
    "raw_biomarkers": "PIK3CA-mutated, hormone receptor-positive, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Piqray (alpelisib), fulvestrant"
  },
  {
    "id": "ind:hc.retevmo:0",
    "document_id": "doc:hc.retevmo",
    "indication": "RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved selpercatinib as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.",
    "raw_biomarkers": "RET fusion-positive",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Retevmo (selpercatinib)"
  },
  {
    "id": "ind:hc.retevmo:1",
    "document_id": "doc:hc.retevmo",
    "indication": "RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved selpercatinib as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.",
    "raw_biomarkers": "RET-mutant",
    "raw_cancer_type": "unresectable advanced or metastatic medullary thyroid cancer (MTC)",
    "raw_therapeutics": "Retevmo (selpercatinib)"
  },
  {
    "id": "ind:hc.retevmo:2",
    "document_id": "doc:hc.retevmo",
    "indication": "RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved selpercatinib as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.",
    "raw_biomarkers": "RET fusion-positive",
    "raw_cancer_type": "advanced or metastatic differentiated thyroid carcinoma",
    "raw_therapeutics": "Retevmo (selpercatinib)"
  },
  {
    "id": "ind:hc.revlimid:0",
    "document_id": "doc:hc.revlimid",
    "indication": "REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved lenalidomide for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogentic abnormalities.",
    "raw_biomarkers": "5q deletion",
    "raw_cancer_type": "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes",
    "raw_therapeutics": "Revlimid (lenalidomide)"
  },
  {
    "id": "ind:hc.rituxan:0",
    "document_id": "doc:hc.rituxan",
    "indication": "RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin\u2019s lymphoma.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin\u2019s lymphoma.",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "relapsed or refractory low-grade or follicular B-cell non-Hodgkin\u2019s lymphoma",
    "raw_therapeutics": "RITUXAN (rituximab for injection)"
  },
  {
    "id": "ind:hc.rituxan:1",
    "document_id": "doc:hc.rituxan",
    "indication": "RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin\u2019s lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin\u2019s lymphoma (DLBCL) in combination with CHOP chemotherapy.",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "diffuse large B-cell non-Hodgkin\u2019s lymphoma (DLBCL)",
    "raw_therapeutics": "RITUXAN (rituximab for injection), CHOP chemotherapy"
  },
  {
    "id": "ind:hc.rituxan:2",
    "document_id": "doc:hc.rituxan",
    "indication": "RITUXAN (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved rituximab for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy.",
    "raw_biomarkers": "CD20 positive",
    "raw_cancer_type": "Stage III/IV follicular B-cell non-Hodgkin's lymphoma",
    "raw_therapeutics": "RITUXAN (rituximab for injection), CVP chemotherapy"
  },
  {
    "id": "ind:hc.rozlytrek:0",
    "document_id": "doc:hc.rozlytrek",
    "indication": "ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",
    "raw_biomarkers": "NTRK gene fusion",
    "raw_cancer_type": "unresectable locally advanced or metastatic extracranial solid tumours",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:hc.rozlytrek:1",
    "document_id": "doc:hc.rozlytrek",
    "indication": "ROZLYTREK (entrectinib) is indicated for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved entrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Rozlytrek (entrectinib)"
  },
  {
    "id": "ind:hc.rybrevant:0",
    "document_id": "doc:hc.rybrevant",
    "indication": "RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.",
    "raw_biomarkers": "EGFR Eexon 19 deletions or Exon 21 L858R substitution mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Rybrevant (amivantamab), carboplatin, pemetrexed"
  },
  {
    "id": "ind:hc.rybrevant:1",
    "document_id": "doc:hc.rybrevant",
    "indication": "RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.",
    "raw_biomarkers": "EGFR Exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Rybrevant (amivantamab), carboplatin, pemetrexed"
  },
  {
    "id": "ind:hc.rybrevant:2",
    "document_id": "doc:hc.rybrevant",
    "indication": "RYBREVANT (amivantamab for injection) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved amivantamab as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.",
    "raw_biomarkers": "EGFR Exon 20 insertion mutations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Rybrevant (amivantamab)"
  },
  {
    "id": "ind:hc.rydapt:0",
    "document_id": "doc:hc.rydapt",
    "indication": "RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).",
    "raw_biomarkers": "FLT3 mutation",
    "raw_cancer_type": "acute myeloid leukemia (AML)",
    "raw_therapeutics": "Rydapt (midostaurin), cytarabine, daunorubicin"
  },
  {
    "id": "ind:hc.scemblix:0",
    "document_id": "doc:hc.scemblix",
    "indication": "SCEMBLIX (asciminib tablets) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors.",
    "raw_biomarkers": "Philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Scemblix (asciminib)"
  },
  {
    "id": "ind:hc.sprycel:0",
    "document_id": "doc:hc.sprycel",
    "indication": "SPRYCEL (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dasatinib for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.",
    "raw_biomarkers": "Philadelphia chromosome positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML) in chronic phase",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:hc.sprycel:1",
    "document_id": "doc:hc.sprycel",
    "indication": "SPRYCEL (dasatinib) is indicated for the treatment of adults with Ph+ chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dasatinib for the treatment of adults with Ph+ chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate.",
    "raw_biomarkers": "Philadelphia chromosome positive (Ph+)",
    "raw_cancer_type": "chronic, accelerated, or blast phase chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:hc.sprycel:2",
    "document_id": "doc:hc.sprycel",
    "indication": "SPRYCEL (dasatinib) is indicated for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dasatinib for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.",
    "raw_biomarkers": "Philadelphia chromosome positive (Ph+)",
    "raw_cancer_type": "acute lymphoblastic leukemia (ALL)",
    "raw_therapeutics": "Sprycel (dasatinib)"
  },
  {
    "id": "ind:hc.tabrecta:0",
    "document_id": "doc:hc.tabrecta",
    "indication": "TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved capmatinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.",
    "raw_biomarkers": "MET exon 14 skipping",
    "raw_cancer_type": " locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tabrecta (capmatinib)"
  },
  {
    "id": "ind:hc.tafinlar:0",
    "document_id": "doc:hc.tafinlar",
    "indication": "TAFINLAR (dabrafenib mesylate) is indicated as a monotherapy, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
    "raw_biomarkers": "unresectable or metastatic melanoma",
    "raw_cancer_type": "BRAF V600 mutation",
    "raw_therapeutics": "Tafinlar (dabrafenib mesylate)"
  },
  {
    "id": "ind:hc.tafinlar:1",
    "document_id": "doc:hc.tafinlar",
    "indication": "TAFINLAR (dabrafenib mesylate), in combination with trametinib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dabrafenib mesylate, in combination with trametinib for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.",
    "raw_biomarkers": "BRAF V600E or V600K",
    "raw_cancer_type": "melanoma",
    "raw_therapeutics": "Tafinlar (dabrafenib mesylate), trametinib"
  },
  {
    "id": "ind:hc.tafinlar:2",
    "document_id": "doc:hc.tafinlar",
    "indication": "TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tafinlar (dabrafenib mesylate), trametinib"
  },
  {
    "id": "ind:hc.tafinlar:3",
    "document_id": "doc:hc.tafinlar",
    "indication": "TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "low-grade glioma (LGG)",
    "raw_therapeutics": "Tafinlar (dabrafenib mesylate), trametinib"
  },
  {
    "id": "ind:hc.tafinlar:4",
    "document_id": "doc:hc.tafinlar",
    "indication": "TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.",
    "raw_biomarkers": "BRAF V600E",
    "raw_cancer_type": "high-grade glioma (HGG)",
    "raw_therapeutics": "Tafinalr (dabrafenib mesylate), trametinib"
  },
  {
    "id": "ind:hc.tagrisso:0",
    "document_id": "doc:hc.tagrisso",
    "indication": "TAGRISSO (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved osimertinib as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R substitution",
    "raw_cancer_type": "stage IB-IIIA1 non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:hc.tagrisso:1",
    "document_id": "doc:hc.tagrisso",
    "indication": "TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved osimertinib for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during opr following platinum based chemoradiation therapy.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R substitution",
    "raw_cancer_type": "locally advanced, unresectable non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:hc.tagrisso:2",
    "document_id": "doc:hc.tagrisso",
    "indication": "TAGRISSO (osimertinib) is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved osimertinib for the first-line  treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R substitution",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:hc.tagrisso:3",
    "document_id": "doc:hc.tagrisso",
    "indication": "TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",
    "raw_biomarkers": "EGFR exon 19 deletions or exon 21 L858R substitution",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy"
  },
  {
    "id": "ind:hc.tagrisso:4",
    "document_id": "doc:hc.tagrisso",
    "indication": "TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved osimertinib for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.",
    "raw_biomarkers": "EGFR T790M",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tagrisso (osimertinib)"
  },
  {
    "id": "ind:hc.talzenna:0",
    "document_id": "doc:hc.talzenna",
    "indication": "TALZENNA (talazoparib) is indicated as a monotherapy for the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curative radiation or surgery) or metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting, unless patients were inappropriate for these treatments.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved talazoparib as a monotherapy for the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curative radiation or surgery) or metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting, unless patients were inappropriate for these treatments.",
    "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Talzenna (talazoparib)"
  },
  {
    "id": "ind:hc.tasigna:0",
    "document_id": "doc:hc.tasigna",
    "indication": "TASIGNA (nilotinib) 150 mg and 200 mg capsules are indicated for The treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nilotinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:hc.tasigna:1",
    "document_id": "doc:hc.tasigna",
    "indication": "TASIGNA (nilotinib) 150mg and 200mg capsules are indicated for the treatment of pediatric patients 2 years of age and older with newly diagnosed Ph+ CML-CP.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved tasigna for the treatment of the treatment of pediatric patients 2 years of age and older with newly diagnosed Ph+ CML-CP.",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:hc.tasigna:2",
    "document_id": "doc:hc.tasigna",
    "indication": "TASIGNA (nilotinib) 150 mg and 200 mg capsules are indicated for the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nilotinib for The treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:hc.tasigna:3",
    "document_id": "doc:hc.tasigna",
    "indication": "TASIGNA (nilotinib) 150 mg and 200 mg capsules are indicated for the treatment of pediatric patients 2 years of age and older with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved nilotinib for the treatment of pediatric patients 2 years of age and older with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.",
    "raw_biomarkers": "philadelphia chromosome-positive (Ph+)",
    "raw_cancer_type": "chronic myeloid leukemia (CML)",
    "raw_therapeutics": "Tasigna (nilotinib)"
  },
  {
    "id": "ind:hc.tecentriq:0",
    "document_id": "doc:hc.tecentriq",
    "indication": "TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA* NSCLC whose tumours have PD-L1 expression on \u2265 50% of tumour cells (TCs)",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved",
    "raw_biomarkers": "PD-L1 \u2265 50%",
    "raw_cancer_type": "non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:hc.tecentriq:1",
    "document_id": "doc:hc.tecentriq",
    "indication": "TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained \u2265 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering \u2265 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved atezolizumab as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained \u2265 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering \u2265 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.",
    "raw_biomarkers": "PD-L1 >= 50% or PD-L1 >= 10% TIIC, no EGFR or ALK genomic tumour aberrations.",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:hc.tecentriq:2",
    "document_id": "doc:hc.tecentriq",
    "indication": "TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous NSCLC.",
    "raw_biomarkers": "no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-squamous non small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab), bevacizumab, paclitaxel, carboplatin"
  },
  {
    "id": "ind:hc.tecentriq:3",
    "document_id": "doc:hc.tecentriq",
    "indication": "TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated in combination with nab-paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous, non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved atezolizumab in combination with nab-paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous, non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.",
    "raw_biomarkers": "no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-squamous, non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab), nab-paclitaxel, carboplatin"
  },
  {
    "id": "ind:hc.tecentriq:4",
    "document_id": "doc:hc.tecentriq",
    "indication": "TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving TECENTRIQ.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved atezolizumab for the treatment of adult patients with locally advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving TECENTRIQ.",
    "raw_biomarkers": "EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Tecentriq (atezolizumab)"
  },
  {
    "id": "ind:hc.tecentriq:5",
    "document_id": "doc:hc.tecentriq",
    "indication": "TECENTRIQ (atezolizumab) in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering \u2265 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering \u2265 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.",
    "raw_biomarkers": "PD-L1 >= 1%",
    "raw_cancer_type": "unresectable locally advanced or metastatic triple-negative breast cancer",
    "raw_therapeutics": "Tecentriq (atezolizumab), nab-paclitaxel"
  },
  {
    "id": "ind:hc.tepmetko:0",
    "document_id": "doc:hc.tepmetko",
    "indication": "TEPMETKO (tepotinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved tepotinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.",
    "raw_biomarkers": "MET exon 14 skipping",
    "raw_cancer_type": "locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "TEPMETKO (tepotinib)"
  },
  {
    "id": "ind:hc.tibsovo:0",
    "document_id": "doc:hc.tibsovo",
    "indication": "TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.",
    "raw_biomarkers": "IDH1 R132 mutation",
    "raw_cancer_type": "acute myeloid leukemia (AML)",
    "raw_therapeutics": "Tibsovo (ivosidenib), azacitidine"
  },
  {
    "id": "ind:hc.tibsovo:1",
    "document_id": "doc:hc.tibsovo",
    "indication": "TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.",
    "raw_biomarkers": "IDH1 R132",
    "raw_cancer_type": "locally advanced or metastatic cholangiocarcinoma",
    "raw_therapeutics": "Tibsovo (ivosidenib)"
  },
  {
    "id": "ind:hc.trodelvy:0",
    "document_id": "doc:hc.trodelvy",
    "indication": "TRODELVY (sacituzumab govitecan) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved sacituzumab govitecan for the treatment of adult  patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",
    "raw_biomarkers": "HR-positive, HER2-negative,",
    "raw_cancer_type": "unresectable locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Trodelvy (sacituzumab govitecan)"
  },
  {
    "id": "ind:hc.truqap:0",
    "document_id": "doc:hc.truqap",
    "indication": "TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",
    "raw_biomarkers": "HR-positive, HER2-negative, PIK3CA/AKT1/PTEN alterations",
    "raw_cancer_type": "locally advanced or metastatic breast cancer",
    "raw_therapeutics": "Truqap (capivasertib), fulvestrant"
  },
  {
    "id": "ind:hc.tukysa:0",
    "document_id": "doc:hc.tukysa",
    "indication": "TUKYSA (tucatinib) is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.",
    "raw_biomarkers": "HER2-positive",
    "raw_cancer_type": "locally advanced unresectable or metastatic breast cancer",
    "raw_therapeutics": "Tukysa (tucatinib), trastuzumab, capecitabine"
  },
  {
    "id": "ind:hc.tykerb:0",
    "document_id": "doc:hc.tykerb",
    "indication": "TYKERB (lapatinib tablets) is indicated for in combination with capecitabine, for the treatment of patients with metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have progressed on taxanes and anthracycline before starting this therapy. In addition, patients should have progressed on prior trastuzumab therapy in the metastatic setting.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved lapatinib in combination with capecitabine, for the treatment of patients with metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have progressed on taxanes and anthracycline before starting this therapy. In addition, patients should have progressed on prior trastuzumab therapy in the metastatic setting.",
    "raw_biomarkers": "HER2 overexpression",
    "raw_cancer_type": "metastatic breast cancer",
    "raw_therapeutics": "Tykerb (lapatinib), capecitabine"
  },
  {
    "id": "ind:hc.vectibix:0",
    "document_id": "doc:hc.vectibix",
    "indication": "VECTIBIX (panitumumab for injection) is indicated for the treatment of previously untreated patients with non-mutated (wild-type) RAS metastatic colorectal carcinoma (mCRC) in combination with FOLFOX (infusional 5-fluorouracil, leucovorin, and oxaliplatin).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved panitumumab in combination with FOLFOX (infusional 5-fluorouracil, leucovorin, and oxaliplatin) for the treatment of previously untreated patients with non-mutated (wild-type) RAS metastatic colorectal carcinoma (mCRC).",
    "raw_biomarkers": "wild-type KRAS, wild-type NRAS",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Vectibix (panitumumab), FOLFOX (infusional 5-fluorouracil, leucovorin, and oxaliplatin)."
  },
  {
    "id": "ind:hc.vectibix:1",
    "document_id": "doc:hc.vectibix",
    "indication": "VECTIBIX (panitumumab for injection) is indicated as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved panitumumab as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.",
    "raw_biomarkers": "wild-type KRAS, wild-type NRAS",
    "raw_cancer_type": "metastatic colorectal carcinoma (mCRC)",
    "raw_therapeutics": "Vectibix (panitumumab)"
  },
  {
    "id": "ind:hc.verzenio:0",
    "document_id": "doc:hc.verzenio",
    "indication": "VERZENIO (abemaciclib) is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "early breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib), endocrine therapy"
  },
  {
    "id": "ind:hc.verzenio:1",
    "document_id": "doc:hc.verzenio",
    "indication": "VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.",
    "raw_biomarkers": "HR-positive, HER2-negative",
    "raw_cancer_type": "advanced or metastatic breast cancer",
    "raw_therapeutics": "Verzenio (abemaciclib), aromatase inhibitor, fulvestrant"
  },
  {
    "id": "ind:hc.vitrakvi:0",
    "document_id": "doc:hc.vitrakvi",
    "indication": "VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.",
    "raw_biomarkers": "NTRK gene fusion",
    "raw_cancer_type": "solid tumours",
    "raw_therapeutics": "Vitrakvi (larotrectinib)"
  },
  {
    "id": "ind:hc.voranigo:0",
    "document_id": "doc:hc.voranigo",
    "indication": "VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.",
    "raw_biomarkers": "IDH1 mutation or IDH2 mutation",
    "raw_cancer_type": "Grade 2a astrocytoma or oligodendroglioma",
    "raw_therapeutics": "Voranigo (vorasidenib)"
  },
  {
    "id": "ind:hc.vyloy:0",
    "document_id": "doc:hc.vyloy",
    "indication": "Vyloy (zolbetuximab for injection), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive as determined by a validated test.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved zolbetuximab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive as determined by a validated test.",
    "raw_biomarkers": "HER2-negative, CLDN18.2 >= 75%",
    "raw_cancer_type": "locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma",
    "raw_therapeutics": "Vyloy (zolbetuximab), fluoropyrimidine, platinum-containing chemotherapy"
  },
  {
    "id": "ind:hc.xalkori:0",
    "document_id": "doc:hc.xalkori",
    "indication": "XALKORI (crizotinib) is indicated for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved crizotinib for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "XALKORI (crizotinib)"
  },
  {
    "id": "ind:hc.xalkori:1",
    "document_id": "doc:hc.xalkori",
    "indication": "XALKORI (crizotinib) is indicated for use in patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved crizotinib for use in patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": "ROS1-positive",
    "raw_cancer_type": "locally advanced or metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "XALKORI (crizotinib)"
  },
  {
    "id": "ind:hc.xospata:0",
    "document_id": "doc:hc.xospata",
    "indication": "XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.",
    "raw_biomarkers": "FLT3 mutation",
    "raw_cancer_type": "relapsed or refactory acute myeloid leukemia (AML)",
    "raw_therapeutics": "Xospata (gilteritinib)"
  },
  {
    "id": "ind:hc.yervoy:0",
    "document_id": "doc:hc.yervoy",
    "indication": "YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 \u2265 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 \u2265 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",
    "raw_biomarkers": "PD-L1 \u2265 1% with no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Yervoy (ipilimumab), nivolumab"
  },
  {
    "id": "ind:hc.yervoy:1",
    "document_id": "doc:hc.yervoy",
    "indication": "YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",
    "raw_biomarkers": "no EGFR or ALK genomic tumour aberrations",
    "raw_cancer_type": "metastatic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Yervoy (ipilimumab), nivolumab, 2 cycles of platinum-doublet chemotherapy"
  },
  {
    "id": "ind:hc.yervoy:2",
    "document_id": "doc:hc.yervoy",
    "indication": "YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.",
    "raw_biomarkers": "MSI-H, dMMR",
    "raw_cancer_type": "metastatic colorectal cancer",
    "raw_therapeutics": "Yervoy (ipilimumab), nivolumab"
  },
  {
    "id": "ind:hc.yervoy:3",
    "document_id": "doc:hc.yervoy",
    "indication": "YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression \u2265 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression \u2265 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",
    "raw_biomarkers": "PD-L1 \u2265 1%",
    "raw_cancer_type": "unresectable or metastatic esophageal squamous cell carcinoma (ESCC)",
    "raw_therapeutics": "Yervoy (ipilimumab), nivolumab"
  },
  {
    "id": "ind:hc.zelboraf:0",
    "document_id": "doc:hc.zelboraf",
    "indication": "ZELBORAF (vemurafenib) is indicated as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved vemurafenib as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.",
    "raw_biomarkers": "BRAF V600",
    "raw_cancer_type": "unresectable or metastatic melanoma",
    "raw_therapeutics": "Zelboraf (vemurafenib)"
  },
  {
    "id": "ind:hc.zykadia:0",
    "document_id": "doc:hc.zykadia",
    "indication": "ZYKADIA (ceritinib) as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ceritinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "metastaic non-small cell lung cancer (NSCLC)",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:hc.zykadia:1",
    "document_id": "doc:hc.zykadia",
    "indication": "ZYKADIA (ceritinib) as monotherapy is indicated for the treatment of adult patients with ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib.",
    "initial_approval_date": null,
    "initial_approval_url": null,
    "description": "Health Canada approved ceritinib for the treatment of adult patients with ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib.",
    "raw_biomarkers": "ALK-positive",
    "raw_cancer_type": "locally advanced or metastatic NSCLC",
    "raw_therapeutics": "Zykadia (ceritinib)"
  },
  {
    "id": "ind:fda.modeyso:0",
    "document_id": "doc:fda.modeyso",
    "indication": "MODEYSO is a protease activator indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.",
    "initial_approval_date": "2025-08-06",
    "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219876s000lbl.pdf",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. H3 K27M The underlying trials, including ONC018 (NCT03134131), assessed H3 K27M status through either IHC or sequencing for patient eligibility. The H3 K27M nomenclature refers to the H3-3A:c.83A>T p.K28M (K27M) variant.",
    "raw_biomarkers": "H3 K27M",
    "raw_cancer_type": "diffuse midline glioma",
    "raw_therapeutics": "Modeyso (dordaviprone)",
    "date_regular_approval": null,
    "date_accelerated_approval": "2025-08-06",
    "status": "Accelerated"
  }
]
